NovoCure Limited (NVCR) 10-K27 Feb 202019 FY Annual reportFinancial data

Company Profile

Cover

Cover - USD ($)	12 Months Ended
Cover - USD ($)	Dec. 31, 2019	Feb. 19, 2020	Jun. 28, 2019
Cover page.
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2019
Document Transition Report	false
Entity File Number	001-37565
Entity Registrant Name	NovoCure Limited
Entity Incorporation, State or Country Code	Y9
Entity Tax Identification Number	98-1057807
Entity Address, Address Line One	No. 4 The Forum
Entity Address, Address Line Two	Grenville Street
Entity Address, City or Town	St. Helier
Entity Address, Country	JE
Entity Address, Postal Zip Code	JE2 4UF
Country Region	+44
City Area Code	(0) 15
Local Phone Number	3475 6700
Title of 12(b) Security	Ordinary shares, no par value per share
Trading Symbol	NVCR
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 3,943,182,013
Entity Common Stock, Shares Outstanding		99,640,549
Documents Incorporated by Reference	Portions of the registrant’s definitive proxy statement for its 2020 annual meeting of shareholders are incorporated by reference into Items 10, 11, 12, 13, and 14 of Part III of this Form 10-K. Such definitive proxy statement will be filed with the Securities and Exchange Commission within 120 days after the end of the registrant’s fiscal year ended December 31, 2019.
Amendment Flag	false
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Entity Central Index Key	0001645113
Current Fiscal Year End Date	--12-31

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 177,321	$ 140,622
Short-term investments	148,769	105,256
Restricted cash	2,095	2,134
Trade receivables, net	58,859	36,523
Receivables and prepaid expenses	29,202	14,279
Inventories	23,701	22,555
Total current assets	439,947	321,369
Long-term assets:
Property and equipment, net	9,342	8,442
Field equipment, net	7,684	6,924
Right-of-use assets, net	17,571
Other long-term assets	4,904	3,058
Total long-term assets	39,501	18,424
Total assets	479,448	339,793
Current liabilities:
Trade payables	36,925	26,708
Other payables and accrued expenses	49,386	37,852
Total current liabilities	86,311	64,560
Long-term liabilities:
Long-term loan, net of discount and issuance costs	149,424	149,268
Deferred revenues	7,807	9,929
Long term leases	14,140
Employee benefit liabilities	3,754	2,683
Other long-term liabilities	222	1,094
Total long-term liabilities	175,347	162,974
Total liabilities	261,658	227,534
Commitments and contingencies
Shareholders’ equity:
Ordinary shares - No par value, Unlimited shares authorized; Issued and outstanding: 99,528,435 shares and 93,254,185 shares at December 31, 2019 and December 31, 2018 respectively;	0	0
Additional paid-in capital	871,442	757,314
Accumulated other comprehensive loss	(2,767)	(1,400)
Accumulated deficit	(650,885)	(643,655)
Total shareholders’ equity	217,790	112,259
Total liabilities and shareholders’ equity	$ 479,448	$ 339,793

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - shares	Dec. 31, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Common stock issued (in shares)	99,528,435	93,254,185
Common stock outstanding (in shares)	99,528,435	93,254,185

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Statement [Abstract]
Net revenues	$ 351,318	$ 248,069	$ 177,026
Cost of revenues	88,606	80,048	55,610
Gross profit	262,712	168,021	121,417
Operating costs and expenses:
Research, development and clinical trials	79,003	50,574	38,103
Sales and marketing	96,675	77,663	63,528
General and administrative	87,948	73,456	59,114
Total operating costs and expenses	263,626	201,693	160,745
Operating income (loss)	(914)	(33,672)	(39,328)
Financial expenses (income), net	7,910	12,270	9,169
Income (loss) before income taxes	(8,824)	(45,942)	(48,497)
Income tax	(1,594)	17,617	13,165
Net income (loss)	$ (7,230)	$ (63,559)	$ (61,662)
Basic and diluted net income (loss) per ordinary share (in usd per share)	$ (0.07)	$ (0.69)	$ (0.70)
Weighted average number of ordinary shares used in computing basic and diluted net income (loss) per share (in shares)	97,237,549	91,828,043	88,546,719

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ (7,230)	$ (63,559)	$ (61,662)
Other comprehensive income (loss), net of tax :
Change in foreign currency translation adjustments	(304)	27	8
Pension benefit plan	(1,063)	(84)	532
Total comprehensive income (loss)	$ (8,597)	$ (63,616)	$ (61,122)

Statements of Changes in Shareh

Statements of Changes in Shareholders' Equity - USD ($) $ in Thousands	Total	Ordinary shares	Additional paid-in capital	Accumulated other comprehensive income (loss)	Retained earnings (accumulated deficit)
Beginning balance at Dec. 31, 2016	$ 142,345		$ 664,154	$ (1,883)	$ (519,926)
Beginning balance (in shares) at Dec. 31, 2016		87,066,446
Share-based compensation to employees	27,116		27,116
Exercise of options and warrants	3,685		3,685
Exercise of options and warrants (in shares)		2,244,153
Issuance of shares in connection with employee stock purchase plan	1,540		1,540
Issuance of shares in connection with employee stock purchase plan (in shares)		167,433
Tax benefit from share-based award activity	0		670		(670)
Other comprehensive income (loss), net of tax (benefit) expense	540			540
Net income (loss)	(61,662)				(61,662)
Ending balance at Dec. 31, 2017	113,564		697,165	(1,343)	(582,258)
Ending balance (in shares) at Dec. 31, 2017		89,478,032
Share-based compensation to employees	39,846		39,846
Exercise of options and warrants	18,468		18,468
Exercise of options and warrants (in shares)		3,688,781
Issuance of shares in connection with employee stock purchase plan	1,835		1,835
Issuance of shares in connection with employee stock purchase plan (in shares)		87,372
Other comprehensive income (loss), net of tax (benefit) expense	(57)			(57)
Net income (loss)	(63,559)				(63,559)
Ending balance at Dec. 31, 2018	112,259		757,314	(1,400)	(643,655)
Ending balance (in shares) at Dec. 31, 2018		93,254,185
Share-based compensation to employees	52,416		52,416
Exercise of options and warrants	59,245		59,245
Exercise of options and warrants (in shares)		6,206,884
Proceeds from issuance of shares	2,467		2,467
Proceeds from issuance of shares (in shares)		67,366
Other comprehensive income (loss), net of tax (benefit) expense	(1,367)			(1,367)
Net income (loss)	(7,230)				(7,230)
Ending balance at Dec. 31, 2019	$ 217,790		$ 871,442	$ (2,767)	$ (650,885)
Ending balance (in shares) at Dec. 31, 2019		99,528,435

Statements of Changes in Shar_2

Statements of Changes in Shareholders' Equity (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Statement of Stockholders' Equity [Abstract]
Other comprehensive income (loss), tax (benefit) expense	$ 145	$ 10	$ (68)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Cash flows from operating activities:
Net income (loss)	$ (7,230)	$ (63,559)	$ (61,662)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	8,460	9,006	7,677
Asset write-downs and impairment of field equipment	398	407	241
Share-based compensation	52,416	39,846	27,116
Foreign currency remeasurement loss (gain)	(917)	0	0
Decrease (increase) in accounts receivables	(36,496)	(10,325)	(21,249)
Amortization of discount (premium)	(2,176)	1,022	252
Decrease (increase) in inventories	(1,159)	(529)	3,524
Decrease (increase) in other long-term assets	3,446	(949)	(554)
Increase (decrease) in accounts payables and accrued expenses	16,883	13,713	13,310
Increase (decrease) in other long-term liabilities	(7,006)	9,503	(1,789)
Net cash provided by (used in) operating activities	26,620	(1,865)	(33,134)
Cash flows from investing activities:
Purchase of property, equipment and field equipment	(10,485)	(6,711)	(7,366)
Proceeds from maturity of short-term investments	420,661	255,000	120,000
Purchase of short-term investments	(461,843)	(253,782)	(104,006)
Net cash provided by (used in) investing activities	(51,667)	(5,493)	8,628
Cash flows from financing activities:
Proceeds from issuance of shares, net	2,467	1,835	1,540
Proceeds from long-term loan, net	0	149,150	19
Repayment of long-term loan	(31)	(100,084)	(76)
Exercise of options and warrants	59,245	18,468	3,685
Net cash provided by financing activities	61,681	69,369	5,168
Effect of exchange rate changes on cash, cash equivalents and restricted cash	26	27	8
Increase (decrease) in cash, cash equivalents and restricted cash	36,660	62,038	(19,330)
Cash, cash equivalents and restricted cash at the beginning of the year	142,756	80,718	100,048
Cash, cash equivalents and restricted cash at the end of the year	179,416	142,756	80,718
Cash paid during the year for:
Income taxes	11,241	20,350	10,286
Interest	13,699	$ 13,334	$ 10,162
Non-cash activities in accordance with ASC-842:
Right-of-use assets obtained in exchange for lease liabilities	$ 22,943

Organization and Basis of Prese

Organization and Basis of Presentation	12 Months Ended
Organization and Basis of Presentation	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Basis of Presentation	Organization NovoCure Limited (including its consolidated subsidiaries, the "Company") was incorporated in the Bailiwick of Jersey and is principally engaged in the development, manufacture and commercialization of Tumor Treating Fields delivery systems, including Optune and NovoTTF-100L (our "Products"), for the treatment of solid tumor cancers. The Company has received regulatory approval from the U.S. Food and Drug Administration ("FDA") under the Premarket Approval pathway and regulatory approvals and clearances in certain other countries for Optune to treat adult patients with glioblastoma. The Company also has received FDA approval under the Humanitarian Device Exemption pathway to market NovoTTF-100L for unresectable, locally advanced or metastatic malignant pleural mesothelioma in combination with standard chemotherapies. During the year ended December 31, 2019, the Company implemented changes to its corporate entity operating structure, including transferring certain intellectual property to its Swiss subsidiary, primarily to align corporate entities with the Company’s evolving operations and business model. See Note 13.

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	12 Months Ended
Basis of Presentation and Significant Accounting Policies	Dec. 31, 2019
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	Basis of presentation and significant accounting policies The consolidated financial statements are prepared according to United States generally accepted accounting principles ("U.S. GAAP"). a. Use of estimates: The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company evaluates on an ongoing basis its assumptions, including those related to contingencies, deferred taxes, tax liabilities, useful-life of field equipment, right-of-use assets and lease liabilities, pension liabilities, revenue recognition, and share-based compensation costs. The Company’s management believes that the estimates, judgment and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities at the dates of the consolidated financial statements, and the reported amounts of net revenue and expenses during the reporting period. Actual results could differ from those estimates. b. Financial statements in U.S. dollars: The accompanying financial statements have been prepared in U.S. dollars in thousands, except for share and per-share data. The Company finances its operations in U.S. dollars and a substantial portion of its costs and revenues from its primary markets is incurred in U.S. dollars. As such, the Company’s management believes that the U.S. dollar is the currency of the primary economic environment in which NovoCure Limited and certain subsidiaries operate. The Company’s reporting currency is U.S. dollars. Transactions and balances denominated in U.S. dollars are presented at their original amounts. Monetary accounts maintained in currencies other than the U.S. dollar are re-measured into dollars in accordance with Accounting Standards Codification (ASC) No. 830-10, "Foreign Currency Matters." All transaction gains and losses of the re-measurement of monetary balance sheet items are reflected in the consolidated statements of operations as financial income or expenses, as applicable. For a subsidiary whose functional currency has been determined to be its local currency, assets and liabilities are translated at year-end exchange rates and statement of operations items are translated at average exchange rates prevailing during the year. Such translation adjustments are recorded as a separate component of accumulated other comprehensive income (loss) in shareholders' equity. c. Principles of consolidation: The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. Intercompany transactions and balances, including unrealized profits from intercompany sales, have been eliminated upon consolidation. d. Cash equivalents: Cash equivalents are short-term, highly liquid investments that are readily convertible into cash with a maturity of three months or less at the date acquired. e. Short-term investments and restricted cash: 1. Short-term investments: The Company accounts for investments in debt securities in accordance with ASC 320, "Investments—Debt and Equity Securities." Management determines the appropriate classification of its investments in marketable debt securities at the time of purchase and reevaluates such determinations at each balance sheet date. For the years ended December 31, 2019 and 2018, all securities are classified as held-to-maturity since the Company has the intent and ability to hold the securities to maturity and, accordingly, debt securities are stated at amortized cost. The amortized cost of held-to-maturity securities is adjusted for amortization of premiums and accretion of discounts to maturity and any other than temporary impairment losses. Such amortization and interest are included in the consolidated statement of operations as financial income or expenses, as appropriate. For the three years ended December 31, 2019, no impairment losses have been identified. 2. Restricted cash: The Company has restricted cash used as security for the use of Company credit cards, presented in short-term assets. Additionally, the Company has pledged bank deposits to cover bank guarantees related to facility rental agreements, fleet lease agreements and customs payments presented in other long-term assets (see Note 12). f. Trade receivables: The Company’s trade receivables balance contains billed and unbilled commercial activities. As needed, the Company records an allowance for doubtful accounts by reserving for specifically identified doubtful accounts. The Company periodically reviews its customers’ credit risk and payment history. To date, the Company has not experienced any material credit losses related to counter-party risk. g. Inventories: Inventories are stated at the lower of cost or net realizable value. Cost is determined using the weighted average method. The Company regularly evaluates its ability to realize the value of inventory. If the inventories are deemed damaged, if actual demand for the Company’s delivery systems deteriorates, or if market conditions are less favorable than those projected, inventory write-offs may be required. Inventory write-offs of $310, $684, and $489, respectively, were recorded for the years ended December 31, 2019, 2018 and 2017. h. Property and equipment: Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following rates: % Computers and laboratory equipment 15 - 33 Office furniture 6 - 33 Production equipment 20 Leasehold improvements Over the shorter of the term of the lease or its useful life i. Field equipment: Field equipment is stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful life of the field equipment, which was determined to be 18 to 36 months. Field equipment is equipment being utilized under service agreements, and accounted for in accordance with ASC 842 on a monthly basis as an operating lease (see Note 2(w)). The Company records a write-off provision for any excess, lost or damaged equipment when warranted based on an assessment of the equipment. Write-offs for equipment are included in cost of revenues. During the years ended December 31, 2019, 2018 and 2017, write-offs for $327, $350, and $195, respectively, were recorded (see Note 7). j. Impairment of long-lived assets: The Company’s long-lived assets are reviewed for impairment in accordance with ASC 360-10, "Property, Plant and Equipment," whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. During the three years ended December 31, 2019, no impairment losses have been identified. k. Other long-term assets: Restricted deposits and long-term lease deposits associated with office rent and vehicles under operating leases are presented in other long-term assets. l. Revenue recognition: Our Products are comprised of two main components: (1) an electric field generator and (2) transducer arrays and related accessories. We retain title to the electric field generator, and the patient is provided replacement transducer arrays and technical support for the device during the term of treatment. The electric field generator and transducer arrays are always supplied and function together and are not sold on a standalone basis. In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2014-9, Revenue from Contracts with Customers (Topic 606) (ASU 2014-9), an updated standard on revenue recognition and issued subsequent amendments to the initial guidance in March 2016, April 2016, May 2016 and December 2016 within ASU 2016-8, 2016-10, 2016-12 and 2016-20, respectively (collectively, "ASC 606"). The core principle of the new standard is for companies to recognize revenue to depict the transfer of goods and services to patients in amounts that reflect the consideration to which the company expects to be entitled in exchange for those goods and services. In addition, the new standard requires expanded disclosures. The Company has adopted the standard effective January 1, 2018 using the modified retrospective method for all contracts. The reported results for 2018 and 2019 reflect the application of ASC 606 guidance while the reported results for 2017 were prepared under the guidance of ASC 605, Revenue Recognition (ASC 605). The amount of revenue recognized in 2018 and 2019 reflects the consideration to which the Company expects to be entitled to receive in exchange for our Products. The Company uses the portfolio approach to apply the standard to portfolios of contracts with similar characteristics. To recognize revenue under ASC 606, the Company applies the following five steps: 1. Identify the contract with a patient. A contract with a patient exists when (i) the Company enters into an enforceable contract with a patient that defines each party’s rights regarding delivery of and payment for a Product, (ii) the contract has commercial substance and (iii) the Company determines that collection of substantially all consideration for such Product is probable based on the payer’s intent and ability to pay the promised consideration. The evidence of a contract generally consists of a prescription, a patient service agreement and the verification of the assigned payer for the contract and intention to collect. 2. Identify the performance obligations in the contract. Our contracts include the lease of the device, the supply obligation of disposable transducer arrays and technical support for the term of treatment. To the extent a contract includes multiple promised products and/or services, the Company must apply judgment to determine whether those products and/or services are capable of being distinct in the context of the contract. If these criteria are not met the promised products and/or services are accounted for as a combined performance obligation. In the Company’s case, the device, support, and disposables are provided as one inseparable package of monthly treatment for a single monthly fee. For more information, see Note 2(w). 3. Determine the transaction price. The transaction price is determined based on the consideration to which the Company will be entitled in exchange for providing a Product to the patient. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing either the expected value method or the most likely amount method depending on the nature of the variable consideration. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. The Company has agreements with many payers that define explicit discounts off the gross transaction price. In addition to the explicit discounts negotiated with each payer, the Company expects to receive, in aggregate for a given portfolio, less than the gross revenue net of explicit discounts. ASC 606 requires that the Company recognize this variable consideration as an implicit discount in the billing period. The implicit discount includes both an estimate of claims that will pay at an amount less than billed and an estimate of claims that will not pay within a given time horizon. The implicit discount adjustments to the transaction price are due to concessions, not collectability concerns driven by payer credit risk. 4. Allocate the transaction price to performance obligations in the contract. If a contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. As discussed above, there is a combined performance obligation under the Company’s contracts and, therefore, the monthly transaction price determined for the performance obligation will be recognized over time ratably over the monthly term of the treatment. 5. Recognize revenue when or as the Company satisfies a performance obligation. The Company satisfies performance obligations over time. Revenue is recognized at the time the related performance obligation is satisfied by transferring a promised service to a patient. The patient consumes the benefits of treatment on a daily basis over the monthly term. As this criterion is met, the revenues will be recognized over the monthly term. For more information, see Note 2(w). At adoption of ASC 606 on January 1, 2018, trade receivables increased by $2,807, deferred revenues increased by $645 and the Company recorded a cumulative impact to its accumulated deficit of $2,162 in 2018. Total deferred revenues balances at December 31, 2019 and 2018 were $19,580 and $18,769, respectively, presented as short-term and long-term liabilities. Unbilled revenues include revenues recognized for therapy provided and not invoiced in the reported period, and are presented as part of accounts receivable. Revenues are presented net of indirect taxes. Net revenues in 2019 and 2018 also include amounts recognized pursuant to the Zai Agreement. For additional information, see Note 12. m. Charitable care: The Company provides treatment at no charge to patients who meet certain criteria under its charitable care policy. Because the Company does not pursue collection of amounts determined to qualify as charity, they are not reported as revenue. The Company's costs of care provided under charitable care were $2,847, $2,762 and $1,483 for the years ended December 31, 2019, 2018 and 2017, respectively. These amounts were determined by applying charitable care as a percentage of gross billings to total cost of goods sold. n. Shipping and handling costs: The Company does not separately bill its customers for shipping and handling costs associated with shipping Products to its customers. These direct shipping and handling costs of $2,688, $2,936 and $5,322 for the years ended December 31, 2019, 2018 and 2017, respectively are included in Sales and Marketing costs. o. Accounting for share-based compensation: The Company accounts for share-based compensation in accordance with ASC 718, "Compensation—Stock Compensation." ASC 718 requires companies to estimate the fair value of share-based compensation awards on the date of grant using an option-pricing model. The value of the award is recognized as an expense over the requisite service periods in the Company’s consolidated statements of operations. The Company's policy is to account for forfeitures as they occur. The Company recognizes compensation costs for the value of awards granted using the accelerated method over the requisite service period of the award, which is generally the restricted share unit vesting term of three years and option vesting term of four years, respectively. The Company applies the Black-Scholes model as it believes it is the most appropriate fair value method for all equity awards and for the Employee Share Purchase Plan (the "ESPP"). For market condition awards, the Company also applies the Monte-Carlo simulation model. The Black-Scholes model requires a number of assumptions, of which the most significant are the share price, expected volatility and the expected award term. The computation of expected volatility is based on actual historical share price volatility of comparable companies when there is not sufficient historical information for the Company. Expected term of options granted is calculated using the average between the vesting period and the contractual term to the expected term of the options in effect at the time of grant. The Company has historically not paid dividends and has no foreseeable plans to pay dividends and, therefore, uses an expected dividend yield of zero in the option pricing model. The risk-free interest rate is based on the yield of U.S. treasury bonds with equivalent terms. p. Fair value of financial instruments: The carrying amounts of cash and cash equivalents, short-term investments, restricted cash, receivables and prepaid expenses, trade receivables, trade payables and other accounts payable and accrued expenses approximate their fair value due to the short-term maturity of such instruments. Based upon the borrowing terms and conditions currently available to the Company, the carrying values of the long-term loans approximate fair value. The Company accounts for certain assets and liabilities at fair value under ASC 820, "Fair Value Measurements and Disclosures." Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. The Company categorizes each of its fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. The three levels of inputs that may be used to measure fair value are as follows: Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets; Level 2 - Includes other inputs that are directly or indirectly observable in the marketplace, other than quoted prices included in Level 1, such as quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets with insufficient volume or infrequent transactions, or other inputs that are observable (model-derived valuations in which significant inputs are observable), or can be derived principally from or corroborated by observable market data; and Level 3 - Unobservable inputs which are supported by little or no market activity. The availability of observable inputs can vary from instrument to instrument and is affected by a wide variety of factors, including, for example, the type of instrument, the liquidity of markets and other characteristics particular to the transaction. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment and the instrument is categorized as Level 3. q. Basic and diluted net loss per share: Basic net income (loss) per share is computed based on the weighted average number of ordinary shares outstanding during each period. Diluted net income per share is computed based on the weighted average number of ordinary shares outstanding during the period, plus potential dilutive shares considered outstanding during the period, in accordance with ASC 260-10, as determined under the treasury stock method. As the inclusion of all potential dilutive shares (deriving from options, RSUs and the ESPP) outstanding would be anti-dilutive, basic and diluted net loss per ordinary share was the same for each full year presented. See Note 19 for additional information regarding the three month periods ended September 30, 2019 and December 31, 2019. r. Income taxes: The Company accounts for income taxes in accordance with ASC 740-10, "Income Taxes." ASC 740-10 prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, to reduce deferred tax assets to their estimated realizable value, if needed. The Company established reserves for uncertain tax positions based on the evaluation of whether or not the Company’s uncertain tax position is "more likely than not" to be sustained upon examination. The Company records interest and penalties pertaining to its uncertain tax positions in the financial statements as income tax expense. s. Concentration of risks: Our cash, cash equivalents, short-term investments and trade receivables are potentially subject to a concentration of risk. Cash, cash equivalents and short-term investments are invested at top tier financial institutions globally. As such, these investments may be in excess of insured limitations or not insured in certain jurisdictions. Generally, these investments may be redeemed upon demand and therefore, bear minimal risk. The Company has no off-balance sheet concentrations of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements. t. Retirement, pension and severance plans: The Company has a 401(k) retirement savings plan for its U.S. employees. Each eligible employee may elect to contribute a portion of the employee’s compensation to the plan. Company contributions to the plan are at the sole discretion of the Company's Board of Directors. Currently, the Company provides a matching contribution of 50% of the employee's contributions, up to a maximum of three percent (3%) of the employee's annual salary. The Company began making matching contributions as of January 1, 2019 and, as of December 31, 2019, the Company had made matching contributions in the amount of $978 pursuant to the plan. The Company sponsors a defined benefit plan (the "Swiss Plan") for all its employees in Switzerland for retirement benefits, as well as benefits on death or long-term disability, whereby the employee and the Company contribute a portion of the employee's compensation to the plan. The Swiss Plan is part of a collective pension fund managed by a top tier insurance company. The Company’s exposure under the Swiss Plan is insured. The Company has financial exposure under the Swiss Plan only in the event that the insurance company does not meet its obligations. The Company accounts for this potential counterparty risk in accordance with ASC 715, "Compensation – Retirement Benefits" (see Note 9). The pension expense for the years ended December 31, 2019, 2018 and 2017 was $984, $882 and $1,036, respectively. Israeli law generally requires payment of severance pay upon dismissal of an employee or upon termination of employment in certain other circumstances. The Company contributes to employee pension plans to fund its severance liabilities. According to Section 14 of Israel Severance Pay Law, the Company makes deposits on behalf of its employees with respect to the Company’s severance liability and therefore no obligation is provided for in the financial statements. Severance pay liabilities with respect to employees who are not subject to Section 14, are provided for in the financial statements based upon the number of years of service and the latest monthly salary and the related deposits are recorded as an asset based on the cash surrender value. Contributions pursuant to these obligations for the years ended December 31, 2019, 2018 and 2017 amounted to $784, $526 and $506, respectively. u. Contingent liabilities: The Company accounts for its contingent liabilities in accordance with ASC 450, "Contingencies." A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter. v. Other comprehensive income (loss): The Company accounts for comprehensive income (loss) in accordance with ASC 220, "Comprehensive Income." ASC 220 establishes standards for the reporting and display of comprehensive income (loss) and its components. Comprehensive income (loss) generally represents all changes in shareholders' equity during the period except those resulting from investments by, or distributions to, shareholders. The accumulated other comprehensive income (loss), net of taxes, relates to a pension liability and foreign currency translation adjustments. w. Leases: 1. Lessee accounting: On January 1, 2019, the Company adopted ASU No. 2016-02, Leases (ASC 842). The Company determines if an arrangement is a lease and the classification of that lease at inception based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right to substantially all the economic benefits from the use of the asset throughout the period, and (3) whether the Company has a right to direct the use of the asset. The Company elected to not recognize a lease liability or right-of-use ("ROU") asset for leases with a term of twelve months or less. The Company also elected the practical expedient to not separate lease and non-lease components for its leases. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make minimum lease payments arising from the lease. ROU assets are initially measured at amounts, which represents the discounted present value of the lease payments over the lease, plus any initial direct costs incurred. The ROU assets are reviewed for impairment. The lease liability is initially measured at lease commencement date based on the discounted present value of minimum lease payments over the lease term. The implicit rate within the operating leases are generally not determinable; therefore, the Company uses the Incremental Borrowing Rate ("IBR") based on the information available at commencement date in determining the present value of lease payments. The Company’s IBR is estimated to approximate the interest rate on similar terms and payments and in economic environments where the leased asset is located. Certain leases include options to extend or terminate the lease. An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain that the Company will exercise that option. An option to terminate is considered unless it is reasonably certain that the Company will not exercise the option. 2. Lessor accounting - Operating leases: ASC 842 provides lessors with an optional practical expedient, by class of underlying asset, not to separate non-lease components from the associated lease component and, instead, to account for those components as a single component if the non-lease components otherwise would be accounted for under the new revenue guidance (ASC 606) and both of the following criteria are met: 1. The timing and pattern of transfer of the lease component and the non-lease component(s) are the same; and 2. The lease component would be classified as an operating lease if it were accounted for separately. The Company's product supply agreements include the right to use the device (lease component), the supply obligation of disposable transducer arrays and technical support for the term of treatment (non-lease component). If the lease component is the predominant component, the Company accounts for all revenues under such lease as a single component in accordance with the new lease accounting standard. Conversely, if the non-lease component is the predominant component, all revenues under such lease are accounted for in accordance with the revenue recognition accounting standard. The Company's operating leases qualify for the single component accounting, and the non-lease component in each of the Company's leases is predominant. Therefore, The Company accounts for all revenues from its operating leases in accordance with the revenue recognition accounting standard. x. Recently adopted accounting pronouncements: In 2016, the FASB issued ASU No. 2016-02, "Leases (Topic 842)", which amends the existing standards for lease accounting, requiring lessees to recognize most leases on their balance sheets. The new standard establishes a right-of-use model that requires a lessee to recognize a right-of-use asset and lease liability on the balance sheet for all leases. Leases will be classified as finance or operating. The standard is effective for interim and annual reporting periods beginning after December 15, 2018. The provisions of ASU 2016-02 are to be applied using a modified retrospective approach. In July 2018, the FASB issued ASU No. 2018-11, "Targeted Improvements - Leases (Topic 842)" (together with ASU 2016-02, "ASC 842"). This update provides an additional (and optional) transition method to adopt the new leases standard. Under this method, an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Consequently, the prior comparative period’s financials will remain the same as those previously presented. The Company adopted the new standard as of January 1, 2019 and it has also elected to adopt the package of practical expedients permitted in ASC 842. Upon implementation of ASC 842, effective January 1, 2019, the Company recorded an increase in right-of-use assets obtained in exchange for lease liabilities of $15,733 on its opening balance sheet. The standard did not have a material impact to the Company's consolidated statements of comprehensive income. The consolidated financial statements for the year ended December 31, 2019 are presented under the new standard, while comparative years presented are not adjusted and continue to be reported in accordance with Topic 840, Leases. y. Recently issued accounting pronouncements: In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 amends the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, which will result in the more timely recognition of losses. ASU 2016-13 also applies to employee benefit plan accounting, with an effective date of the first quarter of fiscal 2020. The amendments in this update are effective for fiscal years beginning after December 31, 2019, including interim periods within those fiscal years. We have adopted the new standard effective January 1, 2020 and do not expect the adoption of this guidance to have a material impact on the Company's consolidated financial statements. In August 2018, FASB issued ASU 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. The amendments in this ASU align the requirements for capitalizing implementation costs incurred in a hosting arrangement with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The implementation costs incurred in a hosting arrangement that is a service contract should be presented as a prepaid asset in the balance sheet and expensed over the term of the hosting arrangement to the same line item in the statement of income as the costs related to the hosting fees. The guidance in this ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years, and early adoption is permitted including adoption in any interim period. The amendments should be applied either retrospectively or prospectively to all implementation costs incurred after adoption. The Company is currently evaluating the impact that the standard will have, if any, on its consolidated financial statements and related disclosures. In August 2018, the FASB issued ASU 2018-14—Compensation—Retirement Benefits—Defined Benefit Plans—General (Topic 715-20): Disclosure Framework—Changes to the Disclosure Requirements for Defined Benefit Plans. ASU 2018-14 improves disclosure requirements for employers that sponsor defined benefi

Cash and Cash Equivalents and S

Cash and Cash Equivalents and Short-Term Investments	12 Months Ended
Cash and Cash Equivalents and Short-Term Investments	Dec. 31, 2019
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Cash and Cash equivalents and Short-term investments	Cash and Cash equivalents and Short-term investments a. Cash and cash equivalents: Cash equivalents include items almost as liquid as cash, such as certificates of deposit and time deposits with maturity periods of three months or less when purchased. December 31, 2019 2018 Cash $ 18,377 $ 9,197 Money market funds 158,944 131,425 Total cash and cash equivalents $ 177,321 $ 140,622 b. Short-term investments The Company invests in marketable U.S. Treasury Bills ("T-bills") that are classified as held-to-maturity securities. The amortized cost and recorded basis of the T-bills are presented as short-term investments. December 31, 2019 2018 Short-term investments $ 148,769 $ 105,256 Quoted market prices were applied to determine the fair value of cash equivalents and short-term investments, therefore they are categorized as Level 1 in accordance with ASC 820, "Fair Value Measurements and Disclosures." The estimated fair value of our short-term investments as of December 31, 2019 and 2018 was $148,738 and $105,266, respectively.

Receivables and Prepaid Expense

Receivables and Prepaid Expenses	12 Months Ended
Receivables and Prepaid Expenses	Dec. 31, 2019
Receivables And Prepaid Expenses [Abstract]
Receivables and Prepaid Expenses	Receivables and prepaid expenses The following table sets forth the Company’s receivables and prepaid expenses: December 31, 2019 2018 Advances to and receivables from suppliers $ 5,097 $ 4,565 Government authorities 21,382 6,106 Prepaid expenses 2,251 3,531 Others 471 77 $ 29,202 $ 14,279

Inventories

Inventories	12 Months Ended
Inventories	Dec. 31, 2019
Inventory Disclosure [Abstract]
Inventories	Inventories The following table sets forth the Company’s inventories: December 31, 2019 2018 Raw materials $ 3,912 $ 870 Work in process 6,482 8,667 Finished goods 13,308 13,018 $ 23,701 $ 22,555

Property and Equipment, Net

Property and Equipment, Net	12 Months Ended
Property and Equipment, Net	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	Property and equipment, net The following table sets forth the Company’s property and equipment, net: December 31, 2019 2018 Cost: Computers and laboratory equipment $ 15,448 $ 12,220 Office furniture 2,486 2,308 Production equipment 1,237 1,228 Leasehold improvements 4,818 4,192 Total cost $ 23,988 $ 19,948 Accumulated depreciation and amortization (14,647) (11,506) Depreciated cost $ 9,342 $ 8,442 The Company capitalized software costs according to FASB's ASC 350-40, "Accounting for the Costs of Computer Software Developed or Obtained for Internal Use." Cumulative capitalization as of December 31, 2019 and 2018 was $7,199 and $6,256, respectively. Amortization of capitalized software costs for the years ended December 31, 2019, 2018 and 2017 was $1,682, $1,486 and $1,226, respectively. Depreciation expense was $2,080, $1,967 and $1,968 for the years ended December 31, 2019, 2018 and 2017, respectively.

Field Equipment, Net

Field Equipment, Net	12 Months Ended
Field Equipment, Net	Dec. 31, 2019
Field Equipment [Abstract]
Field Equipment, Net	Field equipment, net The following table sets forth the Company’s field equipment, net: December 31, 2019 2018 Field equipment $ 21,075 $ 17,380 Accumulated depreciation (13,391) (10,456) Field equipment, net $ 7,684 $ 6,924 Depreciation expense was $4,631, $5,553 and $4,483 for the years ended December 31, 2019, 2018 and 2017, respectively. Write downs of $326, $350, and $195 were identified for the years ended December 31, 2019, 2018 and 2017, respectively.

Other Payables and Accrued Expe

Other Payables and Accrued Expenses	12 Months Ended
Other Payables and Accrued Expenses	Dec. 31, 2019
Payables and Accruals [Abstract]
Other Payables and Accrued Expenses	Other payables and accrued expenses The following table sets forth the Company’s other payables and accrued expenses: December 31, 2019 2018 Employees and payroll accruals $ 20,904 $ 16,717 Taxes payable and others 12,011 12,263 Deferred revenues 11,773 8,840 Other 4,699 32 $ 49,386 $ 37,852

Employee Benefit Obligations

Employee Benefit Obligations	12 Months Ended
Employee Benefit Obligations	Dec. 31, 2019
Retirement Benefits [Abstract]
Employee Benefit Obligations	Employee benefit obligations The Company's liability in respect of the Swiss Plan (see Note 2(t)) is the projected benefit obligation calculated using the projected unit credit method. The projected benefit obligation as of December 31, 2019 represents the actuarial present value of the estimated future payments required to settle the obligation that is attributable to employee service rendered before that date. Swiss Plan assets are recorded at fair value. Pension expense is presented in the payroll expenses in the various functions in which the employees are engaged. Actuarial gains and losses arising from differences between the actual and the expected return on the Swiss Plan assets are recognized in accumulated other comprehensive income (loss) and amortized over the requisite service period. The Swiss Plan is part of a collective pension foundation of pooled investments managed by a top tier insurance company. The Company and the employees pay retirement contributions, which are defined as a percentage of the employees’ covered salaries. Interest is credited to the employees’ account at the minimum rate provided in the Swiss Plan, which represents the Swiss Plan’s primary asset. The targeted allocation for these funds is as follows: Asset Allocation by Category as of September 30, 2019: Asset allocation (%) Asset Category: Debt Securities 36% Real Estate 26% Equity Securities 33% Others 5% Total 100% The following table sets forth the Swiss Plan’s funded status and amounts recognized in the consolidated financial statements for the year ended December 31, 2019 and 2018: December 31, 2019 2018 Change in Benefit Obligation Projected benefit obligation at beginning of year $ 12,249 $ 10,317 Interest cost 114 64 Company service cost 932 820 Employee contributions 599 486 Prior service cost — — Benefits paid (109) 475 Actuarial loss 1,900 87 Projected benefit obligation at end of year $ 15,685 $ 12,249 Change in Plan Assets Fair value of plan assets at beginning of year $ 9,936 $ 8,243 Actual return on plan assets 1,031 3 Employer contributions 899 729 Employee contributions 599 486 Benefits paid (109) 475 Fair value of plan assets at end of year $ 12,356 $ 9,936 Funded Status at End of year Excess of obligation over assets $ 3,329 $ 2,313 Change in Accrued Benefit Liability Accrued benefit liability at beginning of year $ (2,313) $ (2,074) Company contributions made during year 899 729 Net periodic benefit cost for year (1,024) (874) Net decrease (increase) in accumulated other comprehensive loss (891) (94) Accrued benefit liability at end of year $ (3,329) $ (2,313) December 31, 2019 2018 Non-current plan assets $ 12,357 $ 9,936 Non-current liability 15,686 12,249 Accrued benefit liability at end of year $ (3,329) $ (2,313) Projected Benefit Payments Projected year 1 $ 270 $ 206 Projected year 2 1,434 205 Projected year 3 255 1,158 Projected year 4 260 195 Projected year 5 571 200 Projected years 6-10 2,109 2,859 The fair value of the plan assets is the estimated cash surrender value of the insurance contract at December 31, 2019. The level of inputs used to measure fair value was Level 2. Year ended December 31, 2019 2018 Net Periodic Benefit Cost Service cost $ 932 $ 820 Interest cost (income) 114 69 Expected return on plan assets (97) (54) Amortization of transition obligation 54 65 Amortization of prior service costs (19) (18) Total net periodic benefit cost $ 984 $ 882 Weighted average assumptions: Discount rate as of December 31 0.20 % 0.90% Expected long-term rate of return on assets 0.20 % 0.90% Rate of compensation increase 1.00% 1.00% Mortality and disability assumptions () BVG 2015 GT BVG 2015 GT () Mortality data used for actuarial calculation.

Long-Term Loan, Net of Discount

Long-Term Loan, Net of Discount and Issuance Costs	12 Months Ended
Long-Term Loan, Net of Discount and Issuance Costs	Dec. 31, 2019
Debt Disclosure [Abstract]
Long-Term Loan, Net of Discount and Issuance Costs	Long-term loan, net of discount and issuance costs On February 7, 2018, the Company and certain of its subsidiaries entered into a Loan and Security Agreement ("2018 Loan Agreement") with BioPharma Credit PLC pursuant to which such lender made a term loan to the Company in the principal amount of $150 million (the "2018 Credit Facility"). The term loan, which was drawn in full upon execution of the 2018 Loan Agreement, bears interest at 9.0% per annum, payable quarterly in arrears. The Company used a portion of the proceeds of the 2018 Credit Facility to repay in full the Company’s obligations under its then-existing term loan credit facility and is using the remaining proceeds to fund general corporate purposes. The 2018 Credit Facility will mature on February 7, 2023, at which time any unpaid principal and accrued unpaid interest in respect of the term loan will be due and payable. The Company may prepay the term loan, in full, at any time. The Company must prepay the term loan (i) in full or in part upon the entry into certain licensing arrangements and (ii) in full in the event of a change of control. In each case, any prepayment (whether permitted or mandatory) is subject to a prepayment premium and/or make-whole payment. The prepayment fee if the Company prepays outstanding loan amounts prior to February 7, 2021 is 2.0% and is 1.0% if made after the February 7, 2021 but prior to February 7, 2022.If the Company prepays outstanding loan amounts prior to August 7, 2020, it must pay a make-whole amount equal to the amount of interest that would have accrued on the amount of all principal that is prepaid from the date of such prepayment through February 7, 2021. All obligations under the 2018 Credit Facility are guaranteed by the Company’s current and future direct and indirect subsidiaries. In addition, the obligations under the 2018 Credit Facility are secured by a first-priority security interest in substantially all of the property and assets of, as well as the equity interests owned by, the Company and certain of the other guarantors. The 2018 Credit Facility contains other customary covenants. Total net issuance costs of the 2018 Credit Facility, which were $576 as of December 31, 2019, are presented net of the 2018 Credit Facility proceeds and are amortized to interest expense over the five On February 7, 2018, the Company’s 2015 term loan credit facility was terminated upon the Company’s repayment in full of the term loan issued thereunder. The unamortized discount in the amount of $1,160 and issuance costs in the amount of $1,399 were fully amortized and included in the Company’s finance expenses in the first quarter of 2018.

Other Long-term Liabilities

Other Long-term Liabilities	12 Months Ended
Other Long-term Liabilities	Dec. 31, 2019
Other Liabilities Disclosure [Abstract]
Other Long-term Liabilities	Other long-term liabilities December 31, 2019 2018 Deferred rent liability $ 40 $ 773 Leasehold improvements financing and other 66 94 Unrecognized tax benefits (Note 13(e)) 116 103 Deferred tax liability — 124 $ 222 $ 1,094

Commitments and Contingent Liab

Commitments and Contingent Liabilities	12 Months Ended
Commitments and Contingent Liabilities	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingent Liabilities	Commitments and contingent liabilities a. Operating leases The facilities of the Company are leased under various operating lease agreements for periods ending no later than 2030. The Company also has the option to extend the term of certain facility lease agreements and these are included in the calculation of right-of-use assets. The Company also leases motor vehicles under various operating leases, which expire on various dates, the latest of which is in 2022. Under ASC 842, all leases with durations greater than 12 months, including non-cancelable operating leases, are now recognized on the balance sheet. The aggregated present value of lease agreements, net of deferred rent, is recorded as a long-term asset titled right-of-use assets. The corresponding lease liabilities are split between other payables and long-term lease liabilities. Upon implementation of ASC 842, effective January 1, 2019, the Company recorded an increase in right-of-use assets obtained in exchange for lease obligations of $15,733 on our opening balance sheet. Future minimum lease payments under non-cancelable operating leases as of December 31, 2019, are as follows: December 31, 2019 Future minimum lease payments: 2020 $ 5,046 2021 5,030 2022 3,823 2023 2,524 2024 1,934 Thereafter 4,081 Total future minimum lease payments $ 22,438 Less imputed interest (3,663) Net present value of future minimum lease payments $ 18,775 Current year end Short-term lease liabilities $ 4,635 Long-term lease liabilities 14,140 Net present value of future minimum lease payments $ 18,775 Weighted average of remaining operating lease term (years) 5.54 Weighted average of operating lease discount rate 7.32 % Lease and rental expense for the years ended December 31, 2019, 2018 and 2017 was $4,607, $4,033, and $3,474, respectively. b. Bank guarantee and pledges As of December 31, 2019 and 2018 the Company pledged bank deposits of $1,557 and $1,143, respectively, to cover bank guarantees in respect of its leases of operating facilities and obtained guarantees by the bank for the fulfillment of the Company’s lease commitments of $1,390 and $1,299, respectively. c. Technion Settlement Agreement In the first quarter of 2018, the Company made the final milestone payment of $5.5 million (the "Milestone Payment") to the Technion Research and Development Foundation ("Technion") pursuant to the settlement agreement dated February 10, 2015 (the "Settlement Agreement"). Pursuant to the Settlement Agreement, and in exchange for a release of potential disputes regarding intellectual property developed by our founder and previously assigned to us, the Company was obligated to pay the Milestone Payment to Technion in the quarter following the quarter in which the Company achieved $250.0 million of cumulative net sales (as defined in the Settlement Agreement) (the "Net Sales Milestone"). The Company met the Net Sales Milestone in the fourth quarter of 2017. d. Zai License and Collaboration Agreement On September 10, 2018, the Company entered into a License and Collaboration Agreement (the "Zai Agreement") with Zai Lab (Shanghai) Co., Ltd. ("Zai"). Under the Zai Agreement, the Company granted Zai exclusive rights to commercialize Optune in the field of oncology in China, Hong Kong, Macau and Taiwan ("Greater China"). The Zai Agreement also established a development partnership for Optune in multiple solid tumor indications. In partial consideration for the license grant to Zai for Greater China, the Company was entitled to a non-refundable, up-front license fee in the amount of $15 million (the "License Fee"). The Zai Agreement also provides for certain development, regulatory and commercial milestone payments totaling up to $78 million. Furthermore, pursuant to the Zai Agreement, Zai will pay the Company tiered royalties at percentage rates from 10 up to the mid-teens on the net sales of the licensed products in Greater China. Zai is purchasing licensed products for commercial use exclusively from the Company at the Company’s fully burdened manufacturing cost. Zai paid the License Fee in the fourth quarter of 2018. Net of withholding taxes, the Company received $12.7 million. The Company recognizes revenue pursuant to the License Agreement with Zai in accordance with ASC 606, "Revenue Recognition from Customers." The License Fee, net of withholding taxes, is deferred and recognized over related six e. Paz Litigation In February 2019, a civil claim was filed in the District Court in Haifa, Israel (the "Court"), by Ofir Paz ("Paz"), a former member of the Company's Board of Directors, and EES Investments Ltd., a company wholly owned by Paz (together with Paz, "Plaintiff") against the Company and Prof. Yoram Palti ("Respondents"). Based on Plaintiff's recent motions described below, Plaintiff claims that he is entitled to approximately 1,200,000 ordinary shares (as adjusted for share capital splits since 2003). In May 2019, the Company filed a motion to dismiss the claim that is still pending. Plaintiff has also filed motions in September and December 2019 to add Asaf Danziger as a Respondent and change the basis of his claims from breach of contract to wrongful deregistration. These motions are pending. The Company believes that the complaint is without merit and plans to defend against this claim vigorously. The Company has not accrued any amounts in respect of these claims, as it believes liability is not probable and the amount of any potential liability cannot be reasonably estimated.

Income Taxes

Income Taxes	12 Months Ended
Income Taxes	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes	Income taxes a. Tax provision The provision (benefit) for income taxes from continuing operations is comprised of: Income (loss) before income taxes: Year ended December 31, 2019 2018 2017 United States (U.S.) $ (87,925) $ (114,890) $ (77,654) Non-U.S. 79,101 68,948 29,157 Total income (loss) before income taxes $ (8,824) $ (45,942) $ (48,497) Income tax: Year ended December 31, 2019 2018 2017 Current: U.S. (1) $ (6,143) $ 6,701 $ 8,491 Non-U.S. (2) 4,405 10,568 5,028 Total current $ (1,738) $ 17,269 $ 13,519 Deferred: U.S. $ — — $ (3) Non-U.S. 144 348 (351) Total deferred 144 348 (354) Total income tax provision $ (1,594) $ 17,617 $ 13,165 (1) This change was driven primarily by research and development credits claimed in the U.S. and deductions associated with share-based compensation. (2) This change primarily resulted from amortization of intellectual property rights. b. Theoretical tax The Company's effective tax rate is affected by the tax rates in the various jurisdictions in which the Company operates. For purposes of comparability, the Company used the notional U.S. federal income tax rate of 21% for the 2019 and 2018 tax year and 35% for the 2017 tax year when presenting the Company's reconciliation of the income tax provision. A reconciliation of the provision for income taxes compared with the amounts at the notional federal statutory rate was: Year ended December 31, 2019 2018 2017 Loss before income taxes $ (8,824) $ (45,942) $ (48,497) U.S statutory income tax rate 21.0 % 21.0 % 35.0 % Notional U.S. federal income taxes at statutory rate $ (1,853) $ (9,648) $ (16,974) Non-deductible expenses 741 1,030 3,308 Foreign taxes rate differential (4,216) (6,000) (7,333) Change in valuation allowance (see Note 13(c)) 244,344 28,657 5,742 State income taxes (16,679) 1,957 (9,089) Change in excess tax benefit (26,528) 2,088 2,203 Unamortized intangible assets (189,410) — — Research and Development Credits (2,333) — — Other (5,673) (326) 34,881 Unrecognized tax expense (benefit) 13 (141) 427 Income tax $ (1,594) $ 17,617 $ 13,165 Effective tax rate 18.1 % (38.3) % (27.1) % In 2017, the Tax Cuts and Jobs Act ("TCJA") was signed into law in the U.S. Changes include, but are not limited to, a corporate tax rate decrease from 35% to 21% effective for tax years beginning after December 31, 2017. In accordance with ASC 740, the Company recorded $34.8 million of deferred tax expense in connection with the remeasurement of certain deferred tax assets and liabilities. This was fully offset by a valuation allowance. Accordingly, there was no net impact on the Company’s income tax expense for the year ended December 31, 2017. The Company’s subsidiary in the United States does not have any foreign subsidiaries and, therefore, the remaining provisions of the TCJA have no material impact on the Company's results of operations. December 22, 2018 marked the end of the measurement period for purposes of ASU 2018-05, and the Company concluded that no change was required to its initial assessment. The table below reflects the 2017 net impact of the TCJA: December 31, 2017 ETR before TCJA US Tax Cuts & Jobs Act Impact Reported ETR U.S statutory income taxes rate 35.0 % — % 35.0 % Non-deductible expenses (6.8) — (6.8) Foreign taxes rate differential 15.1 — 15.1 Change in valuation allowance (83.4) 71.5 (11.9) State income taxes 12.8 5.9 18.7 Share based compensation 2.0 (6.5) (4.5) Change in unrecognized taxes expense (0.9) 0.1 (0.8) Other (0.9) (71.0) (71.9) Effective taxes rate (27.1) % — % (27.1) % c. Deferred income tax Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets and liabilities are as follows: December 31, 2019 2018 Deferred tax assets: Implicit discounts recognized under ASC 606 (see Note 2) $ 124,255 $ 99,316 Net operating loss carryforwards (see Note 13(d)) 35,267 843 Share based compensation 12,253 10,886 Deferred revenue 2,450 1,643 Interest limitations 4,028 — Unamortized intangible assets (1) 176,783 — Other temporary differences 2,359 1,384 Total gross deferred tax assets $ 357,395 $ 114,072 Less: valuation allowance (357,012) (112,360) Total deferred tax assets $ 383 $ 1,712 Deferred tax liabilities: Fixed assets 380 1,427 Other liabilities 3 — Total gross deferred tax liabilities $ 383 $ 1,427 Net deferred taxes assets $ — $ 285 (1) The Company recorded a deferred tax asset of $189,410 related to unamortized intangible assets. Amortization of this intangible asset will be straight-line through 2029. As of December 31, 2019, the balance of this deferred tax asset was $176,783, offset by a valuation allowance of the same amount. d. Carryforward loss: As of December 31, 2019, the Company had $108,172 of U.S. federal net operating loss carryforwards ("NOLs") and $128,912 of U.S. state NOLs. The U.S. federal NOLs carry forward indefinitely. Also, approximately $21,524 in U.S. state NOLs carry forward indefinitely, with the remainder expiring from 2022 through 2039. In addition, the Company had $38,603 of non-U.S NOLs as of December 31, 2019. Approximately $618 of the non-U.S. NOLs carry forward indefinitely, with the remainder expiring between 2026 and 2036. e. Uncertain tax benefits: A reconciliation of the beginning and ending balances of uncertain tax benefits is as follows: December 31, 2019 2018 2017 Balance at beginning of the year $ 103 $ 2,827 $ 2,400 Additions (reductions) for taxes positions related current year — (141) 55 Additions (reductions) for taxes positions related to prior years 13 (2,583) 372 Balance at the end of the year $ 116 $ 103 $ 2,827 The Company recognizes interest and penalties related to unrecognized tax benefits in tax expense. During the years ended December 31, 2019, 2018 and 2017, the Company accrued $13, $2 and $95, respectively, for interest and penalties expenses related to uncertain tax positions. We file income tax returns in the U.S. and various state and foreign jurisdictions. We are currently not under examination by the Internal Revenue Service, and any state, local or foreign taxing jurisdictions. Additional tax years within the period 2015 to 2019 remain subject to examination by the U.S. Internal Revenue Service. Furthermore, tax years 2014 to 2019 remain subject to examination in other U.S. state and municipal jurisdictions, as well as foreign jurisdictions.

Share Capital

Share Capital	12 Months Ended
Share Capital	Dec. 31, 2019
Share-based Compensation, Allocation and Classification in Financial Statements [Abstract]
Share Capital	Share capital Share capital is composed as follows: Issued and outstanding Number of shares December 31, 2019 2018 Ordinary shares no par value 99,528,435 93,254,185 a. Warrants: As part of the Series D and E Convertible Preferred share investment agreements, the investors received warrants to purchase ordinary shares. The Company accounted for these warrants as equity instruments based on the guidance of ASC 815, "Derivatives and Hedging," ASC 480-10, "Distinguishing Liabilities from Equity," its related FASB staff positions, ASC 815-40 "Contracts in Entity’s Own Stock" and the AICPA Technical Practice Aid for accounting for preferred shares and warrants, including the roadmap for accounting for freestanding financial instruments indexed to, and potentially settled in, a company’s own stock. In the years ended December 31, 2018 and 2017, warrants to purchase 504,225 and 1,418,711 ordinary shares, respectively, were cashlessly exercised, resulting in the issuance of 437,081 and 803,138 ordinary shares, respectively. Also, in the year ended December 31, 2018 and 2017 warrants to purchase 3,879 and 6,498 ordinary shares, respectively, with an exercise price of $3.59 per share were exercised for cash. No warrants were outstanding as of December 31, 2019 and 2018. b. Share option plans and ESPP: Until the IPO in October 2015, the Company maintained and granted option awards under the 2003 Share Option Plan (the "2003 Plan") and the 2013 Equity Incentive Share Option Plan (the "2013 Plan") for the Company’s officers, directors, employees and advisors. The 2003 Plan and the 2013 Plan terminated as of the IPO as to future awards, but they continue to govern option awards previously granted thereunder. In September 2015, the Company adopted the 2015 Omnibus Incentive Plan (the "2015 Plan"). The Company’s shareholders approved the 2015 Plan in September 2015. Under the 2015 Plan, the Company can issue various types of equity compensation awards such as restricted shares, performance shares, restricted stock units ("RSUs"), performance units, long-term cash award and other share-based awards. Options granted under the 2015 Plan generally have a four three On December 31, 2019, in accordance with the terms of the 2015 Plan, the number of shares available for issuance under the 2015 Plan automatically increased by 4% of the Company’s outstanding ordinary shares as of December 30, 2019. As a result, the number of shares available for issuance under the 2015 Plan increased from 27,035,515 shares to 31,015,695 shares. As of December 31, 2019, 15,826,518 ordinary shares are available for grant under the 2015 Plan. In September 2015, the Company adopted an ESPP to encourage and enable eligible employees to acquire ownership of the Company’s ordinary shares purchased through accumulated payroll deductions on an after-tax basis. The ESPP is intended to be an "employee stock purchase plan" within the meaning of Section 423 of the Code and the provisions of the ESPP will be construed in a manner consistent with the requirements of such section. The Company began its offerings under the ESPP on August 1, 2016. The Company issued 414,559 ordinary shares for the plan periods ended through December 31, 2019. On December 31, 2019, in accordance with the terms of the ESPP, the number of shares available for purchase by eligible employees who participate in the ESPP automatically increased by 1% of the Company’s outstanding ordinary shares outstanding on December 30, 2019. As of December 31, 2019, 4,050,089 ordinary shares are available for offering under the ESPP. The fair value of share-based awards was estimated using the Black-Scholes model for all equity grants. For market condition awards, the Company also applied the Monte-Carlo simulation model, with the following underlying assumptions: Year ended December 31, 2019 2018 2017 Stock Option Plans Expected term (years) 5.50-6.00 5.50-6.25 5.50-6.25 Expected volatility 55%-61% 52%-55% 57%-59% Risk-free interest rate 1.73%-2.40% 2.70%-2.99% 1.97%-2.23% Dividend yield 0.00 % 0.00 % 0.00 % ESPP Expected term (years) 0.50 0.50 0.50 Expected volatility 44%-62% 45%-53% 76%-82% Risk-free interest rate 2.10%-2.51% 1.61%-2.14% 0.62%-1.13% Dividend yield 0.00 % 0.00 % 0.00 % A summary of the status of the Company’s options to purchase ordinary shares as of December 31, 2019 and changes during the year ended on that date is presented below: Year ended December 31, 2019 Number of options Weighted average exercise price Aggregate intrinsic value Outstanding at beginning of year 14,438,215 $ 13.56 Granted 1,552,987 50.45 Exercised (5,466,170) 10.83 Forfeited and cancelled (174,222) 22.11 Outstanding at end of year 10,350,810 $ 20.40 $ 661,150 Exercisable options 3,217,923 $ 15.55 $ 221,146 A summary of the status of the Company’s RSUs as of December 31, 2019 and changes during the year ended on that date is presented below: Year ended December 31, 2019 Number of RSUs Weighted average grant date fair value price Aggregate intrinsic value Unvested at beginning of year 1,613,197 $ 14.04 Granted 634,694 52.28 Vested (740,714) 13.47 Forfeited and cancelled (32,782) 37.84 Unvested at end of year 1,474,395 $ 30.26 $ 124,247 The total equity-based compensation expense related to all of the Company’s equity-based awards recognized for the years ended December 31, 2019, 2018 and 2017, was comprised as follows: Year ended December 31, 2019 2018 2017 Cost of revenues $ 2,231 $ 1,261 $ 467 Research, development and clinical trials 7,570 4,709 3,587 Sales and marketing 11,897 7,393 3,784 General and administrative 30,718 26,483 19,278 Total share-based compensation expense $ 52,416 $ 39,846 $ 27,116 As of December 31, 2019, unamortized share-based compensation costs amounted to $62,498 and are expected to be recognized over a weighted average period of approximately 2.51 years. The weighted average grant date exercise price of the Company’s options granted during the years ended December 31, 2019, 2018 and 2017 were $50.45, $23.73 and $10.53 per share, respectively. The weighted average grant date fair values of the Company’s options forfeited and cancelled during the years ended December 31, 2019, 2018 and 2017 were $22.11, $15.09 and $12.54, respectively. The aggregate intrinsic values for the options exercised during the years ended December 31, 2019, 2018 and 2017 were $266,626, $57,813 and $17,945, respectively. The aggregate intrinsic value is calculated as the difference between the per share exercise price and the deemed fair value of the Company’s ordinary shares for each share subject to an option multiplied by the number of shares subject to options at the date of exercise. The Company deemed the fair value of the Company’s ordinary shares to be $84.27, $33.48 and $20.20 per share as of December 31, 2019, 2018, and 2017, respectively. The options outstanding as of December 31, 2019 are as follows: Exercise price Number of options outstanding Weighted average remaining contractual term Number of options exercisable Weighted average remaining contractual term $ (years) (years) 0.23 - 10.00 2,256,916 6.15 984,380 4.87 10.01 - 20.00 3,205,758 6.83 869,058 5.84 20.01 - 30.00 2,933,518 7.4 1,225,951 6.57 30.01 - 40.00 424,414 8.56 138,534 8.47 40.01 - 50.00 1,347,064 9.29 — — 50.01 - 60.00 44,380 9.39 — — 60.01 - 90.00 138,760 9.7 — — 10,350,810 7.28 3,217,923 5.94

Financial Expenses, Net

Financial Expenses, Net	12 Months Ended
Financial Expenses, Net	Dec. 31, 2019
Interest and Debt Expense [Abstract]
Financial Expenses, Net	Financial expenses, net The following table sets forth the Company’s total financial expenses, net: Year ended December 31, 2019 2018 2017 Financial expenses: Interest expense $ (13,718) $ (13,491) $ (10,261) Amortization of credit facility costs (156) (2,777) (1,111) Foreign currency transaction losses (431) (398) — Others (338) (242) (321) $ (14,643) $ (16,908) $ (11,693) Financial income: Amortization of treasury bills premium $ 2,331 $ 1,986 $ 859 Foreign currency transaction gains — — 549 Interest income 4,402 2,652 1,116 $ 6,733 $ 4,638 $ 2,524 Total financial expenses, net $ (7,910) $ (12,270) $ (9,169)

Basic and Diluted Net Loss Per

Basic and Diluted Net Loss Per Share	12 Months Ended
Basic and Diluted Net Loss Per Share	Dec. 31, 2019
Earnings Per Share [Abstract]
Basic and Diluted Net Loss Per Share	Basic and diluted net loss per share The following table sets forth the computation of the Company’s basic and diluted net loss per ordinary share: Year ended December 31, 2019 2018 2017 Net income (loss) attributable to ordinary shares as reported $ (7,230) $ (63,559) $ (61,662) Shares used in computing net income (loss) per ordinary share, basic and diluted 97,237,549 91,828,043 88,546,719 Net income (loss) per ordinary share, basic and diluted $ (0.07) $ (0.69) $ (0.70) For the full years ended December 31, 2019, 2018 and 2017, all outstanding options, restricted share units and warrants have been excluded from the calculation of the diluted net loss per share since their effect was anti-dilutive. The following table presents the potentially dilutive shares that were excluded from the computation of diluted net income (loss) per share: Year ended December 31, 2019 2018 2017 Options 8,041,159 7,744,521 4,195,762 Restricted share units 1,152,180 1,238,657 641,358 Warrants — — 384,774 Total potential anti-dilutive shares 9,193,339 8,983,178 5,221,894

Subcontractor

Subcontractor	12 Months Ended
Subcontractor	Dec. 31, 2019
Subcontractor [Abstract]
Subcontractor	SubcontractorIn certain markets and for certain key components, the Company is currently dependent upon sole source suppliers used in its delivery systems. The Company’s management believes that in most cases other suppliers could provide similar components at comparable terms. A change of suppliers which requires FDA or other regulatory approval, however, could cause a material delay in manufacturing and a possible loss of sales, which could adversely affect the Company’s operating results and financial position.

Supplemental Information

Supplemental Information	12 Months Ended
Supplemental Information	Dec. 31, 2019
Geographic Areas, Long-Lived Assets [Abstract]
Supplemental Information	Supplemental information The following table presents long-lived assets by location: December 31, 2019 2018 2017 United States $ 8,896 $ 8,289 $ 10,372 Switzerland 3,067 2,513 5,114 Israel 2,753 2,236 2,081 Germany 729 1,054 190 Others 1,581 1,274 310 Total long-lived assets $ 17,026 $ 15,366 $ 18,067 The Company’s net revenues by geographic region, based on the patient’s location are summarized as follows: Year ended December 31, 2019 2018 2017 United States $ 232,805 $ 168,414 $ 134,688 EMEA: Germany 86,564 67,849 40,215 Other EMEA 8,782 4,653 1,820 Japan 17,912 6,351 303 Greater China (1) 5,255 802 — Total net revenues $ 351,318 $ 248,069 $ 177,026 (1) Reflects revenue recognized in accordance with the Zai Agreement, pursuant to which Zai is commercializing Optune in China, Hong Kong, Macau and Taiwan (referred to in this table as "Greater China"). For additional information, see Note 12.

Selected Quarterly Financial In

Selected Quarterly Financial Information (Unaudited)	12 Months Ended
Selected Quarterly Financial Information (Unaudited)	Dec. 31, 2019
Selected Quarterly Financial Information [Abstract]
Selected Quarterly Financial Information (Unaudited)	Selected quarterly financial information (Unaudited) The following table sets forth selected financial information for the Company: 2019 Three months ended December 31 September 30 June 30 March 31 Net revenues $ 99,234 $ 92,062 $ 86,713 $ 73,309 Gross profit 74,448 69,162 65,607 53,495 Operating income (loss) 153 3,855 1,196 (6,118) Net income (loss) 4,260 1,930 (1,270) (12,150) Basic net income (loss) per ordinary share $ 0.04 $ 0.02 $ (0.01) $ (0.13) Weighted average number of ordinary shares used in computing basic net income (loss) per share 99,226,445 98,485,519 96,356,317 94,811,282 Diluted net income (loss) per ordinary share $ 0.04 $ 0.02 $ (0.01) $ (0.13) Weighted average number of ordinary shares used in computing diluted net income (loss) per share 107,911,519 107,604,578 96,356,317 94,811,282 2018 Three months ended December 31 September 30 June 30 March 31 Net revenues $ 69,674 $ 64,756 $ 61,514 $ 52,125 Gross profit 46,646 45,807 41,681 33,887 Operating income (loss) (8,664) (5,246) (7,085) (12,677) Net income (loss) (15,631) (11,694) (15,510) (20,724) Basic and diluted net income (loss) per ordinary share $ (0.17) $ (0.13) $ (0.17) $ (0.23) Weighted average number of ordinary shares used in computing basic and diluted net income (loss) per share 93,083,298 92,911,375 91,331,862 89,985,612 2017 Three months ended December 31 September 30 June 30 March 31 Net revenues $ 53,661 $ 50,109 $ 38,376 $ 34,880 Gross profit 38,021 34,956 25,224 23,216 Operating income (loss) (4,506) (5,919) (15,530) (13,373) Net income (loss) (10,945) (11,498) (21,174) (18,045) Basic and diluted net income (loss) per ordinary share $ (0.12) $ (0.13) $ (0.24) $ (0.21) Weighted average number of ordinary shares used in computing basic and diluted net income (loss) per share 89,389,364 89,125,646 88,218,868 87,452,983

Basis of Presentation and Sig_2

Basis of Presentation and Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Use of Estimates	Use of estimates:The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company evaluates on an ongoing basis its assumptions, including those related to contingencies, deferred taxes, tax liabilities, useful-life of field equipment, right-of-use assets and lease liabilities, pension liabilities, revenue recognition, and share-based compensation costs. The Company’s management believes that the estimates, judgment and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities at the dates of the consolidated financial statements, and the reported amounts of net revenue and expenses during the reporting period. Actual results could differ from those estimates.
Financial Statements in U.S. Dollars	Financial statements in U.S. dollars: The accompanying financial statements have been prepared in U.S. dollars in thousands, except for share and per-share data. The Company finances its operations in U.S. dollars and a substantial portion of its costs and revenues from its primary markets is incurred in U.S. dollars. As such, the Company’s management believes that the U.S. dollar is the currency of the primary economic environment in which NovoCure Limited and certain subsidiaries operate. The Company’s reporting currency is U.S. dollars. Transactions and balances denominated in U.S. dollars are presented at their original amounts. Monetary accounts maintained in currencies other than the U.S. dollar are re-measured into dollars in accordance with Accounting Standards Codification (ASC) No. 830-10, "Foreign Currency Matters." All transaction gains and losses of the re-measurement of monetary balance sheet items are reflected in the consolidated statements of operations as financial income or expenses, as applicable. For a subsidiary whose functional currency has been determined to be its local currency, assets and liabilities are translated at year-end exchange rates and statement of operations items are translated at average exchange rates prevailing during the year. Such translation adjustments are recorded as a separate component of accumulated other comprehensive income (loss) in shareholders' equity.
Principles of Consolidation	Principles of consolidation:The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. Intercompany transactions and balances, including unrealized profits from intercompany sales, have been eliminated upon consolidation.
Cash Equivalents	Cash equivalents:Cash equivalents are short-term, highly liquid investments that are readily convertible into cash with a maturity of three months or less at the date acquired.
Short-term Investments and Restricted Cash	Short-term investments and restricted cash: 1. Short-term investments: The Company accounts for investments in debt securities in accordance with ASC 320, "Investments—Debt and Equity Securities." Management determines the appropriate classification of its investments in marketable debt securities at the time of purchase and reevaluates such determinations at each balance sheet date. For the years ended December 31, 2019 and 2018, all securities are classified as held-to-maturity since the Company has the intent and ability to hold the securities to maturity and, accordingly, debt securities are stated at amortized cost. The amortized cost of held-to-maturity securities is adjusted for amortization of premiums and accretion of discounts to maturity and any other than temporary impairment losses. Such amortization and interest are included in the consolidated statement of operations as financial income or expenses, as appropriate. For the three years ended December 31, 2019, no impairment losses have been identified. 2. Restricted cash:
Trade Receivables	Trade receivables:The Company’s trade receivables balance contains billed and unbilled commercial activities. As needed, the Company records an allowance for doubtful accounts by reserving for specifically identified doubtful accounts. The Company periodically reviews its customers’ credit risk and payment history. To date, the Company has not experienced any material credit losses related to counter-party risk.
Inventories	Inventories:Inventories are stated at the lower of cost or net realizable value. Cost is determined using the weighted average method. The Company regularly evaluates its ability to realize the value of inventory. If the inventories are deemed damaged, if actual demand for the Company’s delivery systems deteriorates, or if market conditions are less favorable than those projected, inventory write-offs may be required.
Property and Field Equipment	Property and equipment:Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following rates: % Computers and laboratory equipment 15 - 33 Office furniture 6 - 33 Production equipment 20 Leasehold improvements Over the shorter of the term of the lease or its useful life i. Field equipment:
Impairment of Long-Lived Assets	Impairment of long-lived assets:The Company’s long-lived assets are reviewed for impairment in accordance with ASC 360-10, "Property, Plant and Equipment," whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value.
Other Long-term Leases	Other long-term assets:Restricted deposits and long-term lease deposits associated with office rent and vehicles under operating leases are presented in other long-term assets.
Revenue Recognition	Revenue recognition: Our Products are comprised of two main components: (1) an electric field generator and (2) transducer arrays and related accessories. We retain title to the electric field generator, and the patient is provided replacement transducer arrays and technical support for the device during the term of treatment. The electric field generator and transducer arrays are always supplied and function together and are not sold on a standalone basis. In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2014-9, Revenue from Contracts with Customers (Topic 606) (ASU 2014-9), an updated standard on revenue recognition and issued subsequent amendments to the initial guidance in March 2016, April 2016, May 2016 and December 2016 within ASU 2016-8, 2016-10, 2016-12 and 2016-20, respectively (collectively, "ASC 606"). The core principle of the new standard is for companies to recognize revenue to depict the transfer of goods and services to patients in amounts that reflect the consideration to which the company expects to be entitled in exchange for those goods and services. In addition, the new standard requires expanded disclosures. The Company has adopted the standard effective January 1, 2018 using the modified retrospective method for all contracts. The reported results for 2018 and 2019 reflect the application of ASC 606 guidance while the reported results for 2017 were prepared under the guidance of ASC 605, Revenue Recognition (ASC 605). The amount of revenue recognized in 2018 and 2019 reflects the consideration to which the Company expects to be entitled to receive in exchange for our Products. The Company uses the portfolio approach to apply the standard to portfolios of contracts with similar characteristics. To recognize revenue under ASC 606, the Company applies the following five steps: 1. Identify the contract with a patient. A contract with a patient exists when (i) the Company enters into an enforceable contract with a patient that defines each party’s rights regarding delivery of and payment for a Product, (ii) the contract has commercial substance and (iii) the Company determines that collection of substantially all consideration for such Product is probable based on the payer’s intent and ability to pay the promised consideration. The evidence of a contract generally consists of a prescription, a patient service agreement and the verification of the assigned payer for the contract and intention to collect. 2. Identify the performance obligations in the contract. Our contracts include the lease of the device, the supply obligation of disposable transducer arrays and technical support for the term of treatment. To the extent a contract includes multiple promised products and/or services, the Company must apply judgment to determine whether those products and/or services are capable of being distinct in the context of the contract. If these criteria are not met the promised products and/or services are accounted for as a combined performance obligation. In the Company’s case, the device, support, and disposables are provided as one inseparable package of monthly treatment for a single monthly fee. For more information, see Note 2(w). 3. Determine the transaction price. The transaction price is determined based on the consideration to which the Company will be entitled in exchange for providing a Product to the patient. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing either the expected value method or the most likely amount method depending on the nature of the variable consideration. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. The Company has agreements with many payers that define explicit discounts off the gross transaction price. In addition to the explicit discounts negotiated with each payer, the Company expects to receive, in aggregate for a given portfolio, less than the gross revenue net of explicit discounts. ASC 606 requires that the Company recognize this variable consideration as an implicit discount in the billing period. The implicit discount includes both an estimate of claims that will pay at an amount less than billed and an estimate of claims that will not pay within a given time horizon. The implicit discount adjustments to the transaction price are due to concessions, not collectability concerns driven by payer credit risk. 4. Allocate the transaction price to performance obligations in the contract. If a contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. As discussed above, there is a combined performance obligation under the Company’s contracts and, therefore, the monthly transaction price determined for the performance obligation will be recognized over time ratably over the monthly term of the treatment. 5. Recognize revenue when or as the Company satisfies a performance obligation. The Company satisfies performance obligations over time. Revenue is recognized at the time the related performance obligation is satisfied by transferring a promised service to a patient. The patient consumes the benefits of treatment on a daily basis over the monthly term. As this criterion is met, the revenues will be recognized over the monthly term. For more information, see Note 2(w). At adoption of ASC 606 on January 1, 2018, trade receivables increased by $2,807, deferred revenues increased by $645 and the Company recorded a cumulative impact to its accumulated deficit of $2,162 in 2018. Total deferred revenues balances at December 31, 2019 and 2018 were $19,580 and $18,769, respectively, presented as short-term and long-term liabilities. Unbilled revenues include revenues recognized for therapy provided and not invoiced in the reported period, and are presented as part of accounts receivable.
Charitable Care	Charitable care:The Company provides treatment at no charge to patients who meet certain criteria under its charitable care policy. Because the Company does not pursue collection of amounts determined to qualify as charity, they are not reported as revenue.
Shipping and Handling Costs	Shipping and handling costs:The Company does not separately bill its customers for shipping and handling costs associated with shipping Products to its customers.
Accounting for Share-based Payments	o. Accounting for share-based compensation: The Company accounts for share-based compensation in accordance with ASC 718, "Compensation—Stock Compensation." ASC 718 requires companies to estimate the fair value of share-based compensation awards on the date of grant using an option-pricing model. The value of the award is recognized as an expense over the requisite service periods in the Company’s consolidated statements of operations. The Company's policy is to account for forfeitures as they occur. The Company recognizes compensation costs for the value of awards granted using the accelerated method over the requisite service period of the award, which is generally the restricted share unit vesting term of three years and option vesting term of four years, respectively. The Company applies the Black-Scholes model as it believes it is the most appropriate fair value method for all equity awards and for the Employee Share Purchase Plan (the "ESPP"). For market condition awards, the Company also applies the Monte-Carlo simulation model. The Black-Scholes model requires a number of assumptions, of which the most significant are the share price, expected volatility and the expected award term. The computation of expected volatility is based on actual historical share price volatility of comparable companies when there is not sufficient historical information for the Company. Expected term of options granted is calculated using the average between the vesting period and the contractual term to the expected term of the options in effect at the time of grant. The Company has historically not paid dividends and has no foreseeable plans to pay dividends and, therefore, uses an expected dividend yield of zero in the option pricing model. The risk-free interest rate is based on the yield of U.S. treasury bonds with equivalent terms.
Fair Value of Financial Instruments	Fair value of financial instruments: The carrying amounts of cash and cash equivalents, short-term investments, restricted cash, receivables and prepaid expenses, trade receivables, trade payables and other accounts payable and accrued expenses approximate their fair value due to the short-term maturity of such instruments. Based upon the borrowing terms and conditions currently available to the Company, the carrying values of the long-term loans approximate fair value. The Company accounts for certain assets and liabilities at fair value under ASC 820, "Fair Value Measurements and Disclosures." Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. The Company categorizes each of its fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. The three levels of inputs that may be used to measure fair value are as follows: Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets; Level 2 - Includes other inputs that are directly or indirectly observable in the marketplace, other than quoted prices included in Level 1, such as quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets with insufficient volume or infrequent transactions, or other inputs that are observable (model-derived valuations in which significant inputs are observable), or can be derived principally from or corroborated by observable market data; and Level 3 - Unobservable inputs which are supported by little or no market activity. The availability of observable inputs can vary from instrument to instrument and is affected by a wide variety of factors, including, for example, the type of instrument, the liquidity of markets and other characteristics particular to the transaction. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment and the instrument is categorized as Level 3.
Basic and Diluted Net Loss Per Share	Basic and diluted net loss per share:Basic net income (loss) per share is computed based on the weighted average number of ordinary shares outstanding during each period. Diluted net income per share is computed based on the weighted average number of ordinary shares outstanding during the period, plus potential dilutive shares considered outstanding during the period, in accordance with ASC 260-10, as determined under the treasury stock method. As the inclusion of all potential dilutive shares (deriving from options, RSUs and the ESPP) outstanding would be anti-dilutive, basic and diluted net loss per ordinary share was the same for each full year presented.
Income Taxes	Income taxes: The Company accounts for income taxes in accordance with ASC 740-10, "Income Taxes." ASC 740-10 prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, to reduce deferred tax assets to their estimated realizable value, if needed. The Company established reserves for uncertain tax positions based on the evaluation of whether or not the Company’s uncertain tax position is "more likely than not" to be sustained upon examination. The Company records interest and penalties pertaining to its uncertain tax positions in the financial statements as income tax expense.
Concentration of Risks	Concentration of risks: Our cash, cash equivalents, short-term investments and trade receivables are potentially subject to a concentration of risk. Cash, cash equivalents and short-term investments are invested at top tier financial institutions globally. As such, these investments may be in excess of insured limitations or not insured in certain jurisdictions. Generally, these investments may be redeemed upon demand and therefore, bear minimal risk. The Company has no off-balance sheet concentrations of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.
Retirement, Pension and Severance Plans	Retirement, pension and severance plans: The Company has a 401(k) retirement savings plan for its U.S. employees. Each eligible employee may elect to contribute a portion of the employee’s compensation to the plan. Company contributions to the plan are at the sole discretion of the Company's Board of Directors. Currently, the Company provides a matching contribution of 50% of the employee's contributions, up to a maximum of three percent (3%) of the employee's annual salary. The Company began making matching contributions as of January 1, 2019 and, as of December 31, 2019, the Company had made matching contributions in the amount of $978 pursuant to the plan. The Company sponsors a defined benefit plan (the "Swiss Plan") for all its employees in Switzerland for retirement benefits, as well as benefits on death or long-term disability, whereby the employee and the Company contribute a portion of the employee's compensation to the plan. The Swiss Plan is part of a collective pension fund managed by a top tier insurance company. The Company’s exposure under the Swiss Plan is insured. The Company has financial exposure under the Swiss Plan only in the event that the insurance company does not meet its obligations. The Company accounts for this potential counterparty risk in accordance with ASC 715, "Compensation –
Contingent Liabilities	Contingent liabilities: The Company accounts for its contingent liabilities in accordance with ASC 450, "Contingencies." A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter.
Other Comprehensive Income (Loss)	Other comprehensive income (loss):The Company accounts for comprehensive income (loss) in accordance with ASC 220, "Comprehensive Income." ASC 220 establishes standards for the reporting and display of comprehensive income (loss) and its components. Comprehensive income (loss) generally represents all changes in shareholders' equity during the period except those resulting from investments by, or distributions to, shareholders. The accumulated other comprehensive income (loss), net of taxes, relates to a pension liability and foreign currency translation adjustments.
Leases	Leases: 1. Lessee accounting: On January 1, 2019, the Company adopted ASU No. 2016-02, Leases (ASC 842). The Company determines if an arrangement is a lease and the classification of that lease at inception based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right to substantially all the economic benefits from the use of the asset throughout the period, and (3) whether the Company has a right to direct the use of the asset. The Company elected to not recognize a lease liability or right-of-use ("ROU") asset for leases with a term of twelve months or less. The Company also elected the practical expedient to not separate lease and non-lease components for its leases. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make minimum lease payments arising from the lease. ROU assets are initially measured at amounts, which represents the discounted present value of the lease payments over the lease, plus any initial direct costs incurred. The ROU assets are reviewed for impairment. The lease liability is initially measured at lease commencement date based on the discounted present value of minimum lease payments over the lease term. The implicit rate within the operating leases are generally not determinable; therefore, the Company uses the Incremental Borrowing Rate ("IBR") based on the information available at commencement date in determining the present value of lease payments. The Company’s IBR is estimated to approximate the interest rate on similar terms and payments and in economic environments where the leased asset is located. Certain leases include options to extend or terminate the lease. An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain that the Company will exercise that option. An option to terminate is considered unless it is reasonably certain that the Company will not exercise the option. 2. Lessor accounting - Operating leases: ASC 842 provides lessors with an optional practical expedient, by class of underlying asset, not to separate non-lease components from the associated lease component and, instead, to account for those components as a single component if the non-lease components otherwise would be accounted for under the new revenue guidance (ASC 606) and both of the following criteria are met: 1. The timing and pattern of transfer of the lease component and the non-lease component(s) are the same; and 2. The lease component would be classified as an operating lease if it were accounted for separately. The Company's product supply agreements include the right to use the device (lease component), the supply obligation of disposable transducer arrays and technical support for the term of treatment (non-lease component). If the lease component is the predominant component, the Company accounts for all revenues under such lease as a single component in accordance with the new lease accounting standard. Conversely, if the non-lease component is the predominant component, all revenues under such lease are accounted for in accordance with the revenue recognition accounting standard. The Company's operating leases qualify for the single component accounting, and the non-lease component in each of the Company's leases is predominant. Therefore, The Company accounts for all revenues from its operating leases in accordance with the revenue recognition accounting standard.
Recently Adopted and Issued Accounting Pronouncement	Recently adopted accounting pronouncements: In 2016, the FASB issued ASU No. 2016-02, "Leases (Topic 842)", which amends the existing standards for lease accounting, requiring lessees to recognize most leases on their balance sheets. The new standard establishes a right-of-use model that requires a lessee to recognize a right-of-use asset and lease liability on the balance sheet for all leases. Leases will be classified as finance or operating. The standard is effective for interim and annual reporting periods beginning after December 15, 2018. The provisions of ASU 2016-02 are to be applied using a modified retrospective approach. In July 2018, the FASB issued ASU No. 2018-11, "Targeted Improvements - Leases (Topic 842)" (together with ASU 2016-02, "ASC 842"). This update provides an additional (and optional) transition method to adopt the new leases standard. Under this method, an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Consequently, the prior comparative period’s financials will remain the same as those previously presented. The Company adopted the new standard as of January 1, 2019 and it has also elected to adopt the package of practical expedients permitted in ASC 842. Upon implementation of ASC 842, effective January 1, 2019, the Company recorded an increase in right-of-use assets obtained in exchange for lease liabilities of $15,733 on its opening balance sheet. The standard did not have a material impact to the Company's consolidated statements of comprehensive income. The consolidated financial statements for the year ended December 31, 2019 are presented under the new standard, while comparative years presented are not adjusted and continue to be reported in accordance with Topic 840, Leases. y. Recently issued accounting pronouncements: In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 amends the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, which will result in the more timely recognition of losses. ASU 2016-13 also applies to employee benefit plan accounting, with an effective date of the first quarter of fiscal 2020. The amendments in this update are effective for fiscal years beginning after December 31, 2019, including interim periods within those fiscal years. We have adopted the new standard effective January 1, 2020 and do not expect the adoption of this guidance to have a material impact on the Company's consolidated financial statements. In August 2018, FASB issued ASU 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. The amendments in this ASU align the requirements for capitalizing implementation costs incurred in a hosting arrangement with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The implementation costs incurred in a hosting arrangement that is a service contract should be presented as a prepaid asset in the balance sheet and expensed over the term of the hosting arrangement to the same line item in the statement of income as the costs related to the hosting fees. The guidance in this ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years, and early adoption is permitted including adoption in any interim period. The amendments should be applied either retrospectively or prospectively to all implementation costs incurred after adoption. The Company is currently evaluating the impact that the standard will have, if any, on its consolidated financial statements and related disclosures. In August 2018, the FASB issued ASU 2018-14—Compensation—Retirement Benefits—Defined Benefit Plans—General (Topic 715-20): Disclosure Framework—Changes to the Disclosure Requirements for Defined Benefit Plans. ASU 2018-14 improves disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans. This standard is effective for fiscal years ending after December 15, 2020, for public business entities. Early adoption is permitted. An entity should apply the amendments in this ASU on a retrospective basis to all periods presented. The Company is currently evaluating the impact that the standard will have, if any, on its consolidated financial statements and related disclosures. In December 2019, the FASB issued Accounting Standard Update No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (ASU 2019-12). This guidance will be effective for the Company in the first quarter of 2021 on a prospective basis, and early adoption is permitted. The Company is currently evaluating the impact of the new guidance on the Company's consolidated financial statements.

Basis of Presentation and Sig_3

Basis of Presentation and Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Property and Equipment at Cost Using Straight-Line Method	Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following rates: % Computers and laboratory equipment 15 - 33 Office furniture 6 - 33 Production equipment 20 Leasehold improvements Over the shorter of the term of the lease or its useful life The following table sets forth the Company’s property and equipment, net: December 31, 2019 2018 Cost: Computers and laboratory equipment $ 15,448 $ 12,220 Office furniture 2,486 2,308 Production equipment 1,237 1,228 Leasehold improvements 4,818 4,192 Total cost $ 23,988 $ 19,948 Accumulated depreciation and amortization (14,647) (11,506) Depreciated cost $ 9,342 $ 8,442

Cash and Cash Equivalents and_2

Cash and Cash Equivalents and Short-Term Investments (Tables)	12 Months Ended
	Dec. 31, 2019
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Summary of Cash and Cash Equivalents	December 31, 2019 2018 Cash $ 18,377 $ 9,197 Money market funds 158,944 131,425 Total cash and cash equivalents $ 177,321 $ 140,622
Summary of Short-Term Investments	December 31, 2019 2018 Short-term investments $ 148,769 $ 105,256

Receivables and Prepaid Expen_2

Receivables and Prepaid Expenses (Tables)	12 Months Ended
Receivables and Prepaid Expenses (Tables)	Dec. 31, 2019
Receivables And Prepaid Expenses [Abstract]
Schedule of Receivables and Prepaid Expenses	The following table sets forth the Company’s receivables and prepaid expenses: December 31, 2019 2018 Advances to and receivables from suppliers $ 5,097 $ 4,565 Government authorities 21,382 6,106 Prepaid expenses 2,251 3,531 Others 471 77 $ 29,202 $ 14,279

Inventories (Tables)

Inventories (Tables)	12 Months Ended
Inventories (Tables)	Dec. 31, 2019
Inventory Disclosure [Abstract]
Schedule of Inventories	The following table sets forth the Company’s inventories: December 31, 2019 2018 Raw materials $ 3,912 $ 870 Work in process 6,482 8,667 Finished goods 13,308 13,018 $ 23,701 $ 22,555

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	12 Months Ended
Property and Equipment, Net (Tables)	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment, Net	Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following rates: % Computers and laboratory equipment 15 - 33 Office furniture 6 - 33 Production equipment 20 Leasehold improvements Over the shorter of the term of the lease or its useful life The following table sets forth the Company’s property and equipment, net: December 31, 2019 2018 Cost: Computers and laboratory equipment $ 15,448 $ 12,220 Office furniture 2,486 2,308 Production equipment 1,237 1,228 Leasehold improvements 4,818 4,192 Total cost $ 23,988 $ 19,948 Accumulated depreciation and amortization (14,647) (11,506) Depreciated cost $ 9,342 $ 8,442

Field Equipment, Net (Tables)

Field Equipment, Net (Tables)	12 Months Ended
Field Equipment, Net (Tables)	Dec. 31, 2019
Field Equipment [Abstract]
Schedule of Field Equipment, Net	The following table sets forth the Company’s field equipment, net: December 31, 2019 2018 Field equipment $ 21,075 $ 17,380 Accumulated depreciation (13,391) (10,456) Field equipment, net $ 7,684 $ 6,924

Other Payables and Accrued Ex_2

Other Payables and Accrued Expenses (Tables)	12 Months Ended
Other Payables and Accrued Expenses (Tables)	Dec. 31, 2019
Payables and Accruals [Abstract]
Schedule of Other Payables and Accrued Expenses	The following table sets forth the Company’s other payables and accrued expenses: December 31, 2019 2018 Employees and payroll accruals $ 20,904 $ 16,717 Taxes payable and others 12,011 12,263 Deferred revenues 11,773 8,840 Other 4,699 32 $ 49,386 $ 37,852

Employee Benefit Obligations (T

Employee Benefit Obligations (Tables)	12 Months Ended
Employee Benefit Obligations (Tables)	Dec. 31, 2019
Retirement Benefits [Abstract]
Schedule of Targeted Allocation for Funds	The targeted allocation for these funds is as follows: Asset Allocation by Category as of September 30, 2019: Asset allocation (%) Asset Category: Debt Securities 36% Real Estate 26% Equity Securities 33% Others 5% Total 100%
Schedule of Change in Benefit Obligations	The following table sets forth the Swiss Plan’s funded status and amounts recognized in the consolidated financial statements for the year ended December 31, 2019 and 2018: December 31, 2019 2018 Change in Benefit Obligation Projected benefit obligation at beginning of year $ 12,249 $ 10,317 Interest cost 114 64 Company service cost 932 820 Employee contributions 599 486 Prior service cost — — Benefits paid (109) 475 Actuarial loss 1,900 87 Projected benefit obligation at end of year $ 15,685 $ 12,249 Change in Plan Assets Fair value of plan assets at beginning of year $ 9,936 $ 8,243 Actual return on plan assets 1,031 3 Employer contributions 899 729 Employee contributions 599 486 Benefits paid (109) 475 Fair value of plan assets at end of year $ 12,356 $ 9,936 Funded Status at End of year Excess of obligation over assets $ 3,329 $ 2,313 Change in Accrued Benefit Liability Accrued benefit liability at beginning of year $ (2,313) $ (2,074) Company contributions made during year 899 729 Net periodic benefit cost for year (1,024) (874) Net decrease (increase) in accumulated other comprehensive loss (891) (94) Accrued benefit liability at end of year $ (3,329) $ (2,313) December 31, 2019 2018 Non-current plan assets $ 12,357 $ 9,936 Non-current liability 15,686 12,249 Accrued benefit liability at end of year $ (3,329) $ (2,313) Projected Benefit Payments Projected year 1 $ 270 $ 206 Projected year 2 1,434 205 Projected year 3 255 1,158 Projected year 4 260 195 Projected year 5 571 200 Projected years 6-10 2,109 2,859
Schedule of Plan Assets Fair Value	The fair value of the plan assets is the estimated cash surrender value of the insurance contract at December 31, 2019. The level of inputs used to measure fair value was Level 2. Year ended December 31, 2019 2018 Net Periodic Benefit Cost Service cost $ 932 $ 820 Interest cost (income) 114 69 Expected return on plan assets (97) (54) Amortization of transition obligation 54 65 Amortization of prior service costs (19) (18) Total net periodic benefit cost $ 984 $ 882 Weighted average assumptions: Discount rate as of December 31 0.20 % 0.90% Expected long-term rate of return on assets 0.20 % 0.90% Rate of compensation increase 1.00% 1.00% Mortality and disability assumptions () BVG 2015 GT BVG 2015 GT () Mortality data used for actuarial calculation.

Other Long-term Liabilities (Ta

Other Long-term Liabilities (Tables)	12 Months Ended
Other Long-term Liabilities (Tables)	Dec. 31, 2019
Other Liabilities Disclosure [Abstract]
Schedule of Other Long-term Liabilities	December 31, 2019 2018 Deferred rent liability $ 40 $ 773 Leasehold improvements financing and other 66 94 Unrecognized tax benefits (Note 13(e)) 116 103 Deferred tax liability — 124 $ 222 $ 1,094

Commitments and Contingent Li_2

Commitments and Contingent Liabilities (Tables)	12 Months Ended
Commitments and Contingent Liabilities (Tables)	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Lease Payments under Non-Cancelable Operating Lease	Future minimum lease payments under non-cancelable operating leases as of December 31, 2019, are as follows: December 31, 2019 Future minimum lease payments: 2020 $ 5,046 2021 5,030 2022 3,823 2023 2,524 2024 1,934 Thereafter 4,081 Total future minimum lease payments $ 22,438 Less imputed interest (3,663) Net present value of future minimum lease payments $ 18,775 Current year end Short-term lease liabilities $ 4,635 Long-term lease liabilities 14,140 Net present value of future minimum lease payments $ 18,775 Weighted average of remaining operating lease term (years) 5.54 Weighted average of operating lease discount rate 7.32 %

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Schedule of Income (Loss) before Income Taxes	Income (loss) before income taxes: Year ended December 31, 2019 2018 2017 United States (U.S.) $ (87,925) $ (114,890) $ (77,654) Non-U.S. 79,101 68,948 29,157 Total income (loss) before income taxes $ (8,824) $ (45,942) $ (48,497)
Schedule of Components of Income Tax Expense (Benefit)	Income tax: Year ended December 31, 2019 2018 2017 Current: U.S. (1) $ (6,143) $ 6,701 $ 8,491 Non-U.S. (2) 4,405 10,568 5,028 Total current $ (1,738) $ 17,269 $ 13,519 Deferred: U.S. $ — — $ (3) Non-U.S. 144 348 (351) Total deferred 144 348 (354) Total income tax provision $ (1,594) $ 17,617 $ 13,165 (1) This change was driven primarily by research and development credits claimed in the U.S. and deductions associated with share-based compensation. (2) This change primarily resulted from amortization of intellectual property rights.
Reconciliation of Provision for Income Taxes	A reconciliation of the provision for income taxes compared with the amounts at the notional federal statutory rate was: Year ended December 31, 2019 2018 2017 Loss before income taxes $ (8,824) $ (45,942) $ (48,497) U.S statutory income tax rate 21.0 % 21.0 % 35.0 % Notional U.S. federal income taxes at statutory rate $ (1,853) $ (9,648) $ (16,974) Non-deductible expenses 741 1,030 3,308 Foreign taxes rate differential (4,216) (6,000) (7,333) Change in valuation allowance (see Note 13(c)) 244,344 28,657 5,742 State income taxes (16,679) 1,957 (9,089) Change in excess tax benefit (26,528) 2,088 2,203 Unamortized intangible assets (189,410) — — Research and Development Credits (2,333) — — Other (5,673) (326) 34,881 Unrecognized tax expense (benefit) 13 (141) 427 Income tax $ (1,594) $ 17,617 $ 13,165 Effective tax rate 18.1 % (38.3) % (27.1) %
Summary of Net Impact of the Tax Cuts and Jobs Act	The table below reflects the 2017 net impact of the TCJA: December 31, 2017 ETR before TCJA US Tax Cuts & Jobs Act Impact Reported ETR U.S statutory income taxes rate 35.0 % — % 35.0 % Non-deductible expenses (6.8) — (6.8) Foreign taxes rate differential 15.1 — 15.1 Change in valuation allowance (83.4) 71.5 (11.9) State income taxes 12.8 5.9 18.7 Share based compensation 2.0 (6.5) (4.5) Change in unrecognized taxes expense (0.9) 0.1 (0.8) Other (0.9) (71.0) (71.9) Effective taxes rate (27.1) % — % (27.1) %
Schedule of Significant Components of Deferred Tax Assets and Liabilities	Significant components of the Company’s deferred tax assets and liabilities are as follows: December 31, 2019 2018 Deferred tax assets: Implicit discounts recognized under ASC 606 (see Note 2) $ 124,255 $ 99,316 Net operating loss carryforwards (see Note 13(d)) 35,267 843 Share based compensation 12,253 10,886 Deferred revenue 2,450 1,643 Interest limitations 4,028 — Unamortized intangible assets (1) 176,783 — Other temporary differences 2,359 1,384 Total gross deferred tax assets $ 357,395 $ 114,072 Less: valuation allowance (357,012) (112,360) Total deferred tax assets $ 383 $ 1,712 Deferred tax liabilities: Fixed assets 380 1,427 Other liabilities 3 — Total gross deferred tax liabilities $ 383 $ 1,427 Net deferred taxes assets $ — $ 285 (1) The Company recorded a deferred tax asset of $189,410 related to unamortized intangible assets. Amortization of this intangible asset will be straight-line through 2029. As of December 31, 2019, the balance of this deferred tax asset was $176,783, offset by a valuation allowance of the same amount.
Schedule of Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits	A reconciliation of the beginning and ending balances of uncertain tax benefits is as follows: December 31, 2019 2018 2017 Balance at beginning of the year $ 103 $ 2,827 $ 2,400 Additions (reductions) for taxes positions related current year — (141) 55 Additions (reductions) for taxes positions related to prior years 13 (2,583) 372 Balance at the end of the year $ 116 $ 103 $ 2,827

Share Capital (Tables)

Share Capital (Tables)	12 Months Ended
Share Capital (Tables)	Dec. 31, 2019
Share-based Compensation, Allocation and Classification in Financial Statements [Abstract]
Schedule of Share Capital	Share capital is composed as follows: Issued and outstanding Number of shares December 31, 2019 2018 Ordinary shares no par value 99,528,435 93,254,185
Schedule of Fair Value Assumptions Used for All Equity Based Awards Estimated Using Black-Scholes Option Pricing Model	The fair value of share-based awards was estimated using the Black-Scholes model for all equity grants. For market condition awards, the Company also applied the Monte-Carlo simulation model, with the following underlying assumptions: Year ended December 31, 2019 2018 2017 Stock Option Plans Expected term (years) 5.50-6.00 5.50-6.25 5.50-6.25 Expected volatility 55%-61% 52%-55% 57%-59% Risk-free interest rate 1.73%-2.40% 2.70%-2.99% 1.97%-2.23% Dividend yield 0.00 % 0.00 % 0.00 % ESPP Expected term (years) 0.50 0.50 0.50 Expected volatility 44%-62% 45%-53% 76%-82% Risk-free interest rate 2.10%-2.51% 1.61%-2.14% 0.62%-1.13% Dividend yield 0.00 % 0.00 % 0.00 %
Schedule of Stock Options to Purchase Ordinary Shares	A summary of the status of the Company’s options to purchase ordinary shares as of December 31, 2019 and changes during the year ended on that date is presented below: Year ended December 31, 2019 Number of options Weighted average exercise price Aggregate intrinsic value Outstanding at beginning of year 14,438,215 $ 13.56 Granted 1,552,987 50.45 Exercised (5,466,170) 10.83 Forfeited and cancelled (174,222) 22.11 Outstanding at end of year 10,350,810 $ 20.40 $ 661,150 Exercisable options 3,217,923 $ 15.55 $ 221,146
Schedule of RSUs	A summary of the status of the Company’s RSUs as of December 31, 2019 and changes during the year ended on that date is presented below: Year ended December 31, 2019 Number of RSUs Weighted average grant date fair value price Aggregate intrinsic value Unvested at beginning of year 1,613,197 $ 14.04 Granted 634,694 52.28 Vested (740,714) 13.47 Forfeited and cancelled (32,782) 37.84 Unvested at end of year 1,474,395 $ 30.26 $ 124,247
Schedule of Equity-Based Compensation Expenses Related to Company's Equity-Based Awards	The total equity-based compensation expense related to all of the Company’s equity-based awards recognized for the years ended December 31, 2019, 2018 and 2017, was comprised as follows: Year ended December 31, 2019 2018 2017 Cost of revenues $ 2,231 $ 1,261 $ 467 Research, development and clinical trials 7,570 4,709 3,587 Sales and marketing 11,897 7,393 3,784 General and administrative 30,718 26,483 19,278 Total share-based compensation expense $ 52,416 $ 39,846 $ 27,116
Schedule of Stock Option Outstanding	The options outstanding as of December 31, 2019 are as follows: Exercise price Number of options outstanding Weighted average remaining contractual term Number of options exercisable Weighted average remaining contractual term $ (years) (years) 0.23 - 10.00 2,256,916 6.15 984,380 4.87 10.01 - 20.00 3,205,758 6.83 869,058 5.84 20.01 - 30.00 2,933,518 7.4 1,225,951 6.57 30.01 - 40.00 424,414 8.56 138,534 8.47 40.01 - 50.00 1,347,064 9.29 — — 50.01 - 60.00 44,380 9.39 — — 60.01 - 90.00 138,760 9.7 — — 10,350,810 7.28 3,217,923 5.94

Financial Expenses, Net (Tables

Financial Expenses, Net (Tables)	12 Months Ended
Financial Expenses, Net (Tables)	Dec. 31, 2019
Interest and Debt Expense [Abstract]
Schedule of Financial Expenses, Net	The following table sets forth the Company’s total financial expenses, net: Year ended December 31, 2019 2018 2017 Financial expenses: Interest expense $ (13,718) $ (13,491) $ (10,261) Amortization of credit facility costs (156) (2,777) (1,111) Foreign currency transaction losses (431) (398) — Others (338) (242) (321) $ (14,643) $ (16,908) $ (11,693) Financial income: Amortization of treasury bills premium $ 2,331 $ 1,986 $ 859 Foreign currency transaction gains — — 549 Interest income 4,402 2,652 1,116 $ 6,733 $ 4,638 $ 2,524 Total financial expenses, net $ (7,910) $ (12,270) $ (9,169)

Basic and Diluted Net Loss Pe_2

Basic and Diluted Net Loss Per Share (Tables)	12 Months Ended
Basic and Diluted Net Loss Per Share (Tables)	Dec. 31, 2019
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Net Loss Per Ordinary Share	The following table sets forth the computation of the Company’s basic and diluted net loss per ordinary share: Year ended December 31, 2019 2018 2017 Net income (loss) attributable to ordinary shares as reported $ (7,230) $ (63,559) $ (61,662) Shares used in computing net income (loss) per ordinary share, basic and diluted 97,237,549 91,828,043 88,546,719 Net income (loss) per ordinary share, basic and diluted $ (0.07) $ (0.69) $ (0.70)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following table presents the potentially dilutive shares that were excluded from the computation of diluted net income (loss) per share: Year ended December 31, 2019 2018 2017 Options 8,041,159 7,744,521 4,195,762 Restricted share units 1,152,180 1,238,657 641,358 Warrants — — 384,774 Total potential anti-dilutive shares 9,193,339 8,983,178 5,221,894

Supplemental Information (Table

Supplemental Information (Tables)	12 Months Ended
Supplemental Information (Tables)	Dec. 31, 2019
Geographic Areas, Long-Lived Assets [Abstract]
Schedule of Long-Lived Assets by Location	The following table presents long-lived assets by location: December 31, 2019 2018 2017 United States $ 8,896 $ 8,289 $ 10,372 Switzerland 3,067 2,513 5,114 Israel 2,753 2,236 2,081 Germany 729 1,054 190 Others 1,581 1,274 310 Total long-lived assets $ 17,026 $ 15,366 $ 18,067
Schedule of Revenues by Geographic Region	The Company’s net revenues by geographic region, based on the patient’s location are summarized as follows: Year ended December 31, 2019 2018 2017 United States $ 232,805 $ 168,414 $ 134,688 EMEA: Germany 86,564 67,849 40,215 Other EMEA 8,782 4,653 1,820 Japan 17,912 6,351 303 Greater China (1) 5,255 802 — Total net revenues $ 351,318 $ 248,069 $ 177,026 (1) Reflects revenue recognized in accordance with the Zai Agreement, pursuant to which Zai is commercializing Optune in China, Hong Kong, Macau and Taiwan (referred to in this table as "Greater China"). For additional information, see Note 12.

Selected Quarterly Financial _2

Selected Quarterly Financial Information (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2019
Selected Quarterly Financial Information [Abstract]
Summary of Selected Quarterly Financial Information (Unaudited)	The following table sets forth selected financial information for the Company: 2019 Three months ended December 31 September 30 June 30 March 31 Net revenues $ 99,234 $ 92,062 $ 86,713 $ 73,309 Gross profit 74,448 69,162 65,607 53,495 Operating income (loss) 153 3,855 1,196 (6,118) Net income (loss) 4,260 1,930 (1,270) (12,150) Basic net income (loss) per ordinary share $ 0.04 $ 0.02 $ (0.01) $ (0.13) Weighted average number of ordinary shares used in computing basic net income (loss) per share 99,226,445 98,485,519 96,356,317 94,811,282 Diluted net income (loss) per ordinary share $ 0.04 $ 0.02 $ (0.01) $ (0.13) Weighted average number of ordinary shares used in computing diluted net income (loss) per share 107,911,519 107,604,578 96,356,317 94,811,282 2018 Three months ended December 31 September 30 June 30 March 31 Net revenues $ 69,674 $ 64,756 $ 61,514 $ 52,125 Gross profit 46,646 45,807 41,681 33,887 Operating income (loss) (8,664) (5,246) (7,085) (12,677) Net income (loss) (15,631) (11,694) (15,510) (20,724) Basic and diluted net income (loss) per ordinary share $ (0.17) $ (0.13) $ (0.17) $ (0.23) Weighted average number of ordinary shares used in computing basic and diluted net income (loss) per share 93,083,298 92,911,375 91,331,862 89,985,612 2017 Three months ended December 31 September 30 June 30 March 31 Net revenues $ 53,661 $ 50,109 $ 38,376 $ 34,880 Gross profit 38,021 34,956 25,224 23,216 Operating income (loss) (4,506) (5,919) (15,530) (13,373) Net income (loss) (10,945) (11,498) (21,174) (18,045) Basic and diluted net income (loss) per ordinary share $ (0.12) $ (0.13) $ (0.24) $ (0.21) Weighted average number of ordinary shares used in computing basic and diluted net income (loss) per share 89,389,364 89,125,646 88,218,868 87,452,983

Basis of Presentation and Sig_4

Basis of Presentation and Significant Accounting Policies - Additional Information (Details) - USD ($)	Jan. 01, 2019	Jan. 01, 2018	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Significant Accounting Policies [Line Items]
Impairment losses on short-term investments															$ 0	$ 0	$ 0
Inventory write-offs															310,000	684,000	489,000
Impairment of long-lived assets															0	0	0
Increase (decrease) in trade receivables															36,496,000	10,325,000	21,249,000
Net revenues			$ 99,234,000	$ 92,062,000	$ 86,713,000	$ 73,309,000	$ 69,674,000	$ 64,756,000	$ 61,514,000	$ 52,125,000	$ 53,661,000	$ 50,109,000	$ 38,376,000	$ 34,880,000	351,318,000	248,069,000	177,026,000
Net income (loss)			4,260,000	$ 1,930,000	$ (1,270,000)	$ (12,150,000)	$ (15,631,000)	$ (11,694,000)	$ (15,510,000)	$ (20,724,000)	$ (10,945,000)	$ (11,498,000)	$ (21,174,000)	$ (18,045,000)	$ (7,230,000)	$ (63,559,000)	$ (61,662,000)
Basic and diluted net income (loss) per ordinary share (in usd per share)							$ (0.17)	$ (0.13)	$ (0.17)	$ (0.23)	$ (0.12)	$ (0.13)	$ (0.24)	$ (0.21)	$ (0.07)	$ (0.69)	$ (0.70)
Deferred revenues balances			$ 19,580,000				$ 18,769,000								$ 19,580,000	$ 18,769,000
Cost related to charitable care															$ 2,847,000	2,762,000	$ 1,483,000
Expected dividend yield															0.00%
Percent of employer matching contribution															50.00%
Contributions															$ 978,000
Pension expense															984,000	882,000	1,036,000
Severance costs															784,000	$ 526,000	$ 506,000
Right-of-use assets obtained in exchange for lease liabilities															$ 22,943,000
Restricted Share Unit
Significant Accounting Policies [Line Items]
Stock awards granted, vesting period															3 years
Option
Significant Accounting Policies [Line Items]
Stock awards granted, vesting period															4 years
Expected dividend yield															0.00%	0.00%	0.00%
Shipping and Handling
Significant Accounting Policies [Line Items]
Direct costs included in sales and marketing costs															$ 2,688,000	$ 2,936,000	$ 5,322,000
Accounting Standards Update 2014-09 \| Difference between Revenue Guidance in Effect before and after Topic 606
Significant Accounting Policies [Line Items]
Increase (decrease) in trade receivables		$ 2,807,000
Increase in deferred revenue		645,000
Cumulative deficit effect adjustment resulting from ASU adoption		$ 2,162,000
Accounting Standards Update 2016-02
Significant Accounting Policies [Line Items]
Right-of-use assets obtained in exchange for lease liabilities	$ 15,733,000
Maximum
Significant Accounting Policies [Line Items]
Employer matching contribution, percent of employees' annual salary															3.00%
Field Equipment Under Operating Leases
Significant Accounting Policies [Line Items]
Equipment write-downs included in cost of revenue															$ 327,000	$ 350,000	$ 195,000
Field Equipment Under Operating Leases \| Minimum
Significant Accounting Policies [Line Items]
Property and equipment useful life															18 months
Field Equipment Under Operating Leases \| Maximum
Significant Accounting Policies [Line Items]
Property and equipment useful life															36 months

Basis of Presentation and Sig_5

Basis of Presentation and Significant Accounting Policies - Property and Equipment at Cost Using Straight-Line Method (Details)	12 Months Ended
	Dec. 31, 2019
Computers and laboratory equipment \| Minimum
Property, Plant and Equipment [Line Items]
Straight line depreciation rate	15.00%
Computers and laboratory equipment \| Maximum
Property, Plant and Equipment [Line Items]
Straight line depreciation rate	33.00%
Office furniture \| Minimum
Property, Plant and Equipment [Line Items]
Straight line depreciation rate	6.00%
Office furniture \| Maximum
Property, Plant and Equipment [Line Items]
Straight line depreciation rate	33.00%
Production equipment
Property, Plant and Equipment [Line Items]
Straight line depreciation rate	2000.00%
Leasehold improvements
Property, Plant and Equipment [Line Items]
Straight line depreciation useful life	Over the shorter of the term of the lease or its useful life

Cash and Cash Equivalents and_3

Cash and Cash Equivalents and Short-Term Investments - Summary of Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	$ 177,321	$ 140,622
Cash
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	18,377	9,197
Money market funds
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	$ 158,944	$ 131,425

Cash and Cash Equivalents and_4

Cash and Cash Equivalents and Short-Term Investments - Summary of Short-Term Investments (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Short-term investments	$ 148,769	$ 105,256

Cash and Cash Equivalents and_5

Cash and Cash Equivalents and Short-Term Investments - Additional Information (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Estimated fair value of short-term investments	$ 148,738	$ 105,266

Receivables and Prepaid Expen_3

Receivables and Prepaid Expenses - Schedule of Receivables and Prepaid Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Receivables And Prepaid Expenses [Abstract]
Advances to and receivables from suppliers	$ 5,097	$ 4,565
Government authorities	21,382	6,106
Prepaid expenses	2,251	3,531
Others	471	77
Receivables and prepaid expenses	$ 29,202	$ 14,279

Inventories - Schedule of Inven

Inventories - Schedule of Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Raw materials	$ 3,912	$ 870
Work in process	6,482	8,667
Finished goods	13,308	13,018
Inventories	$ 23,701	$ 22,555

Property and Equipment, Net - S

Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 23,988	$ 19,948
Accumulated depreciation and amortization	(14,647)	(11,506)
Depreciated cost	9,342	8,442
Computers and laboratory equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	15,448	12,220
Office furniture
Property, Plant and Equipment [Line Items]
Property and equipment, gross	2,486	2,308
Production equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	1,237	1,228
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 4,818	$ 4,192

Property and Equipment, Net - A

Property and Equipment, Net - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 2,080	$ 1,967	$ 1,968
Computer software capitalized	7,199	6,256
Computer software amortized	$ 1,682	$ 1,486	$ 1,226

Field Equipment, Net - Schedule

Field Equipment, Net - Schedule of Field Equipment, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Field Equipment [Abstract]
Field equipment	$ 21,075	$ 17,380
Accumulated depreciation	(13,391)	(10,456)
Field equipment, net	$ 7,684	$ 6,924

Field Equipment, Net - Addition

Field Equipment, Net - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Field Equipment [Line Items]
Depreciation expense	$ 2,080	$ 1,967	$ 1,968
Field equipment
Field Equipment [Line Items]
Depreciation expense	4,631	5,553	4,483
Field Equipment Under Operating Leases
Field Equipment [Line Items]
Write downs	$ 326	$ 350	$ 195

Other Payables and Accrued Ex_3

Other Payables and Accrued Expenses - Schedule of Other Payables and Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Payables and Accruals [Abstract]
Employees and payroll accruals	$ 20,904	$ 16,717
Taxes payable and others	12,011	12,263
Deferred revenues	11,773	8,840
Other	4,699	32
Other payables and accrued expenses	$ 49,386	$ 37,852

Employee Benefit Obligations -

Employee Benefit Obligations - Schedule of Asset Allocation by Category (Details)	Sep. 30, 2019
Defined Benefit Plan Disclosure [Line Items]
Target asset allocations	100.00%
Debt Securities
Defined Benefit Plan Disclosure [Line Items]
Target asset allocations	36.00%
Real Estate
Defined Benefit Plan Disclosure [Line Items]
Target asset allocations	26.00%
Equity Securities
Defined Benefit Plan Disclosure [Line Items]
Target asset allocations	33.00%
Others
Defined Benefit Plan Disclosure [Line Items]
Target asset allocations	5.00%

Employee Benefit Obligations _2

Employee Benefit Obligations - Net Funded Status (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Change in Benefit Obligation
Projected benefit obligation at beginning of year	$ 12,249	$ 10,317
Interest cost	114	64
Company service cost	932	820
Employee contributions	599	486
Prior service cost	0	0
Benefits paid	109	475
Actuarial loss	1,900	87
Projected benefit obligation at end of year	15,685	12,249
Change in Plan Assets
Fair value of plan assets at beginning of year	9,936	8,243
Actual return on plan assets	1,031	3
Employer contributions	899	729
Employee contributions	599	486
Benefits paid	109	475
Fair value of plan assets at end of year	12,356	9,936
Funded Status at End of year
Excess of obligation over assets			$ (3,329)	$ (2,313)
Change in Accrued Benefit Liability
Accrued benefit liability at beginning of year	(2,313)	(2,074)
Company contributions made during year	899	729
Net periodic benefit cost for year	(1,024)	(874)
Net decrease (increase) in accumulated other comprehensive loss	(891)	(94)
Accrued benefit liability at end of year	(3,329)	(2,313)
Non-current plan assets			12,357	9,936
Non-current liability			15,686	12,249
Accrued benefit liability at end of year	$ (3,329)	$ (2,074)	(3,329)	(2,313)
Projected Benefit Payments
Projected year 1			270	206
Projected year 2			1,434	205
Projected year 3			255	1,158
Projected year 4			260	195
Projected year 5			571	200
Projected years 6-10			$ 2,109	$ 2,859

Employee Benefit Obligations _3

Employee Benefit Obligations - Net Periodic Benefit Cost (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Net Periodic Benefit Cost
Service cost	$ 932	$ 820
Interest cost (income)	114	69
Expected return on plan assets	(97)	(54)
Amortization of transition obligation	54	65
Amortization of prior service costs	(19)	(18)
Total net periodic benefit cost	$ 984	$ 882
Weighted average assumptions:
Discount rate as of December 31	0.20%	0.90%
Expected long-term rate of return on assets	0.20%	0.90%
Rate of compensation increase	1.00%	1.00%

Long-Term Loan, Net of Discou_2

Long-Term Loan, Net of Discount and Issuance Costs - Additional Information (Details) - USD ($)	Feb. 07, 2018	Dec. 31, 2019	Mar. 31, 2018
2018 Credit Facility
Line of Credit Facility [Line Items]
Term loan, principal amount	$ 150,000,000
Interest on term loan credit facility	9.00%
Debt issuance costs, net		$ 576,000
Term loan credit facility, maturity term		5 years
2018 Credit Facility \| Prior to February 7, 2021
Line of Credit Facility [Line Items]
Pre-payment fee, percentage	2.00%
2018 Credit Facility \| February 7, 2021 to February 7, 2022
Line of Credit Facility [Line Items]
Pre-payment fee, percentage	1.00%
Term Loan
Line of Credit Facility [Line Items]
Debt issuance costs, net			$ 1,399,000
Debt instrument, un-amortized discount			$ 1,160,000

Other Long-term Liabilities - S

Other Long-term Liabilities - Schedule of Other Long-term Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Other Liabilities Disclosure [Abstract]
Deferred rent liability	$ 40	$ 773
Leasehold improvements financing and other	66	94
Unrecognized tax benefits	116	103
Deferred tax liability	0	124
Other long-term liabilities	$ 222	$ 1,094

Commitments and Contingent Li_3

Commitments and Contingent Liabilities - Additional Information (Details) - USD ($) $ in Thousands	Jan. 01, 2019	Sep. 10, 2018	Feb. 28, 2019	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Loss Contingencies [Line Items]
Right-of-use assets obtained in exchange for lease liabilities																$ 22,943
Lease and rental expense																4,607	$ 4,033	$ 3,474
Pledged bank deposits				$ 1,557				$ 1,143								1,557	1,143
Operating lease commitments				1,390				1,299								1,390	1,299
Net revenues				$ 99,234	$ 92,062	$ 86,713	$ 73,309	69,674	$ 64,756	$ 61,514	$ 52,125	$ 53,661	$ 50,109	$ 38,376	$ 34,880	351,318	248,069	$ 177,026
Zai License and Collaboration Agreement
Loss Contingencies [Line Items]
Non-refundable up-front license fee, amount		$ 15,000
License fees received								$ 12,700
Settlement Agreement
Loss Contingencies [Line Items]
Settlement expense											$ 5,500
Net revenues																	250,000
Pending Litigation \| Paz Litigation
Loss Contingencies [Line Items]
Damages sought (in shares)			1,200,000
Maximum \| Zai License and Collaboration Agreement
Loss Contingencies [Line Items]
Regulatory and commercial milestone payments		$ 78,000
Minimum \| Zai License and Collaboration Agreement \| License
Loss Contingencies [Line Items]
Percentage of tiered royalties rates on net sales		10.00%
Accounting Standards Update 2016-02
Loss Contingencies [Line Items]
Right-of-use assets obtained in exchange for lease liabilities	$ 15,733
Accounting Standards Update 2014-09 \| Zai License and Collaboration Agreement \| License
Loss Contingencies [Line Items]
Liability, revenue recognized																$ 2,115	$ 767
Accounting Standards Update 2014-09 \| Zai License and Collaboration Agreement \| License \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2020-01-01
Loss Contingencies [Line Items]
Revenue recognition period				6 years												6 years

Commitments and Contingent Li_4

Commitments and Contingent Liabilities - Schedule of Future Minimum Lease Payments under Non-Cancelable Operating Leases (Details) $ in Thousands	Dec. 31, 2019USD ($)
Future minimum lease payments:
2020	$ 5,046
2021	5,030
2022	3,823
2023	2,524
2024	1,934
Thereafter	4,081
Total future minimum lease payments	22,438
Less imputed interest	(3,663)
Net present value of future minimum lease payments	18,775
Short-term lease liabilities	4,635
Long-term lease liabilities	14,140
Net present value of future minimum lease payments	$ 18,775
Weighted average of remaining operating lease term (years)	5 years 6 months 14 days
Weighted average of operating lease discount rate	7.32%

Income Taxes - Schedule of Inco

Income Taxes - Schedule of Income (Loss) before Income Taxes, Domestic and Foreign (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
United States (U.S.)	$ (87,925)	$ (114,890)	$ (77,654)
Non-U.S.	79,101	68,948	29,157
Income (loss) before income taxes	$ (8,824)	$ (45,942)	$ (48,497)

Income Taxes - Schedule of Comp

Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Current:
U.S. (1)	$ (6,143)	$ 6,701	$ 8,491
Non-U.S. (2)	4,405	10,568	5,028
Total current	(1,738)	17,269	13,519
Deferred:
U.S.	0	0	(3)
Non-U.S.	144	348	(351)
Total deferred	144	348	(354)
Total income tax provision	$ (1,594)	$ 17,617	$ 13,165

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Taxes [Line Items]
Deferred tax assets and liabilities related to revaluation		$ 34,800
U.S. federal NOLs	$ 108,172
U.S. state NOLs	128,912
Non-U.S NOLs	38,603
Uncertain tax positions, interest and penalties recognized	13	$ 2	$ 95
State and Local Jurisdiction
Income Taxes [Line Items]
NOLs carry forwards indefinitely	21,524
Foreign Tax Authority
Income Taxes [Line Items]
NOLs carry forwards indefinitely	$ 618

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Provision for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Loss before income taxes	$ (8,824)	$ (45,942)	$ (48,497)
U.S statutory income tax rate	21.00%	21.00%	35.00%
Notional U.S. federal income taxes at statutory rate	$ (1,853)	$ (9,648)	$ (16,974)
Non-deductible expenses	741	1,030	3,308
Foreign taxes rate differential	(4,216)	(6,000)	(7,333)
Change in valuation allowance	244,344	28,657	5,742
State income taxes	(16,679)	1,957	(9,089)
Change in excess tax benefit	(26,528)	2,088	2,203
Unamortized intangible assets	(189,410)	0	0
Research and Development Credits	(2,333)	0	0
Other	(5,673)	(326)	34,881
Unrecognized tax expense (benefit)	13	(141)	427
Total income tax provision	$ (1,594)	$ 17,617	$ 13,165
Effective tax rate	18.10%	(38.30%)	(27.10%)

Income Taxes - Summery of Net I

Income Taxes - Summery of Net Impact of the Tax Cuts and Jobs Act (Details)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Taxes [Line Items]
U.S statutory income tax rate	21.00%	21.00%	35.00%
Non-deductible expenses			(6.80%)
Foreign taxes rate differential			15.10%
Change in valuation allowance			(11.90%)
State income taxes			18.70%
Share based compensation			(4.50%)
Effective Income Tax Rate Reconciliation, Tax Contingency, Percent			(0.80%)
Other			(71.90%)
Effective Income Tax Rate Reconciliation, Percent, Total	18.10%	(38.30%)	(27.10%)
ETR before TCJA
Income Taxes [Line Items]
U.S statutory income tax rate			35.00%
Non-deductible expenses			(6.80%)
Foreign taxes rate differential			15.10%
Change in valuation allowance			(83.40%)
State income taxes			12.80%
Share based compensation			2.00%
Effective Income Tax Rate Reconciliation, Tax Contingency, Percent			(0.90%)
Other			(0.90%)
Effective Income Tax Rate Reconciliation, Percent, Total			(27.10%)
US Tax Cuts & Jobs Act Impact
Income Taxes [Line Items]
U.S statutory income tax rate			0.00%
Non-deductible expenses			0.00%
Foreign taxes rate differential			0.00%
Change in valuation allowance			71.50%
State income taxes			5.90%
Share based compensation			(6.50%)
Effective Income Tax Rate Reconciliation, Tax Contingency, Percent			0.10%
Other			(71.00%)
Effective Income Tax Rate Reconciliation, Percent, Total			0.00%

Income Taxes - Schedule of Sign

Income Taxes - Schedule of Significant Components of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Deferred tax assets:
Implicit discounts recognized under ASC 606	$ 124,255	$ 99,316
Net operating loss carryforwards (see Note 13(d))	35,267	843
Share based compensation	12,253	10,886
Deferred revenue	2,450	1,643
Interest limitations	4,028	0
Unamortized intangible assets	176,783	0
Other temporary differences	2,359	1,384
Total gross deferred tax assets	357,395	114,072
Less: valuation allowance	(357,012)	(112,360)
Total deferred tax assets	383	1,712
Deferred tax liabilities:
Fixed assets	380	1,427
Other liabilities	3	0
Total gross deferred tax liabilities	383	1,427
Net deferred taxes assets	0	$ 285
Increase (decrease) in deferred tax asset	$ 189,410

Income Taxes - Schedule of Reco

Income Taxes - Schedule of Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Reconciliation of uncertain tax benefits
Balance at beginning of the year	$ 103	$ 2,827	$ 2,400
Additions (reductions) for taxes positions related current year			55
Additions (reductions) for taxes positions related current year	0	(141)
Additions (reductions) for taxes positions related to prior years	13		372
Additions (reductions) for taxes positions related to prior years		(2,583)
Balance at the end of the year	$ 116	$ 103	$ 2,827

Share Capital - Schedule of Sha

Share Capital - Schedule of Share Capital (Details) - shares	Dec. 31, 2019	Dec. 31, 2018
Share-based Compensation, Allocation and Classification in Financial Statements [Abstract]
Ordinary shares issued (in shares)	99,528,435	93,254,185
Ordinary shares outstanding (in shares)	99,528,435	93,254,185

Share Capital - Additional Info

Share Capital - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended				41 Months Ended
	Dec. 31, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2019
Share Capital [Line Items]
Number of warrants cashless exercised (in shares)			504,225	1,418,711
Warrants exercise price (in usd per share)			$ 3.59	$ 3.59
Warrant outstanding (in shares)	0	0	0		0
Unrecognized compensation cost	$ 62,498	$ 62,498			$ 62,498
Unrecognized compensation cost expected recognition weighted average period		2 years 6 months 3 days
Weighted average grant date exercise price of options granted (in usd per share)		$ 50.45	$ 23.73	10.53
Weighted average grant date fair values options forfeited and cancelled (in usd per share)		$ 22.11	$ 15.09	$ 12.54
Aggregate intrinsic values options exercised		$ 266,626	$ 57,813	$ 17,945
Fair value of ordinary shares (in usd per share)	$ 84.27	$ 84.27	$ 33.48	$ 20.20	$ 84.27
ESPP
Share Capital [Line Items]
Ordinary shares available for grant (in shares)	4,050,089	4,050,089			4,050,089
Percentage of increase in shares outstanding		1.00%
Option
Share Capital [Line Items]
Stock awards granted, vesting period		4 years
RSUs
Share Capital [Line Items]
Stock awards granted, vesting period		3 years
2015 Plan
Share Capital [Line Items]
Percentage increase in number of shares available for issuance	4.00%
Number of shares available for issuance (in shares)	31,015,695	31,015,695	27,035,515		31,015,695
Ordinary shares available for grant (in shares)	15,826,518	15,826,518			15,826,518
2015 Plan \| Option
Share Capital [Line Items]
Stock awards granted, expiration period		10 years
2015 Plan \| RSUs
Share Capital [Line Items]
Stock awards granted, vesting period		3 years
Warrant
Share Capital [Line Items]
Number of shares issued upon the exercise of warrants (in shares)			437,081	803,138
Number of ordinary shares purchased by exercise of warrants (in shares)			3,879	6,498
Ordinary shares
Share Capital [Line Items]
Number of shares issued upon the exercise of warrants (in shares)		67,366
Ordinary shares issued for ESPP (in shares)			87,372	167,433
Ordinary shares \| ESPP
Share Capital [Line Items]
Ordinary shares issued for ESPP (in shares)					414,559

Share Capital - Schedule of Fai

Share Capital - Schedule of Fair Value Assumptions Used Only for Equity Based Awards Estimated Using Black-Scholes Option Pricing Model (Details)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%
ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	6 months	6 months	6 months
Dividend yield	0.00%	0.00%	0.00%
ESPP \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	44.00%	45.00%	76.00%
Risk-free interest rate	2.10%	1.61%	0.62%
ESPP \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	62.00%	53.00%	82.00%
Risk-free interest rate	2.51%	2.14%	1.13%
Stock Option Plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%	0.00%	0.00%
Stock Option Plans \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	5 years 6 months	5 years 6 months	5 years 6 months
Expected volatility	55.00%	52.00%	57.00%
Risk-free interest rate	1.73%	2.70%	1.97%
Stock Option Plans \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	6 years	6 years 3 months	6 years 3 months
Expected volatility	61.00%	55.00%	59.00%
Risk-free interest rate	2.40%	2.99%	2.23%

Share Capital - Schedule of Sto

Share Capital - Schedule of Stock Options to Purchase Ordinary Shares (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Number of options
Number of options, outstanding at beginning of year (in shares)	14,438,215
Number of options, granted (in shares)	1,552,987
Number of options, exercised (in shares)	(5,466,170)
Number of options, forfeited and cancelled (in shares)	(174,222)
Number of options, outstanding at ending of year (in shares)	10,350,810	14,438,215
Number of options, exercisable options (in shares)	3,217,923
Weighted average exercise price
Weighted average exercise price, outstanding at beginning of year (in usd per share)	$ 13.56
Weighted average exercise price, granted (in usd per share)	50.45	$ 23.73	$ 10.53
Weighted average exercise price, exercised (in usd per share)	10.83
Weighted average exercise price, forfeited and cancelled (in usd per share)	22.11
Weighted average exercise price, outstanding at end of year (in usd per share)	20.40	$ 13.56
Weighted average exercise price, exercisable options (in usd per share)	$ 15.55
Aggregate intrinsic value
Aggregate intrinsic value, outstanding at beginning of year
Aggregate intrinsic value, outstanding at end of year	661,150
Aggregate intrinsic value, exercisable options	$ 221,146

Share Capital - Schedule of RSU

Share Capital - Schedule of RSU's (Details) - RSUs $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)$ / sharesshares
Number of RSUs
Number of RSUs, unvested at beginning of year (in shares) \| shares	1,613,197
Number of RSUs, granted (in shares) \| shares	634,694
Number of RSUs, vested (in shares) \| shares	(740,714)
Number of RSUs, forfeited and cancelled (in shares) \| shares	(32,782)
Number of RSUs, unvested at ending of year (in shares) \| shares	1,474,395
Weighted average grant date fair value price
Weighted average grant date fair value price, unvested at beginning of year (in usd per share) \| $ / shares	$ 14.04
Weighted average grant date fair value price, granted (in usd per share) \| $ / shares	52.28
Weighted average grant date fair value price, vested (in usd per share) \| $ / shares	13.47
Weighted average grant date fair value price, forfeited and cancelled (in usd per share) \| $ / shares	37.84
Number of RSUs, unvested at ending of year (in usd per share) \| $ / shares	$ 30.26
Aggregate intrinsic value
Aggregate intrinsic value, unvested at beginning of year \| $
Aggregate intrinsic value, unvested at ending of year \| $	$ 124,247

Share Capital - Equity-Based Co

Share Capital - Equity-Based Compensation Expenses Related to Company's Equity-Based Awards (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense	$ 52,416	$ 39,846	$ 27,116
Cost of Revenues
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense	2,231	1,261	467
Research, Development and Clinical Trials
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense	7,570	4,709	3,587
Sales and Marketing
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense	11,897	7,393	3,784
General and Administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense	$ 30,718	$ 26,483	$ 19,278

Share Capital - Schedule of S_2

Share Capital - Schedule of Stock Option Outstanding (Details) - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of options outstanding (in shares)	10,350,810	14,438,215
Options outstanding, weighted average remaining contractual term	7 years 3 months 10 days
Number of options exercisable (in shares)	3,217,923
Options exercisable, weighted average remaining contractual term	5 years 11 months 8 days
Exercise price 0.23 - 10.00
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of options outstanding (in shares)	2,256,916
Options outstanding, weighted average remaining contractual term	6 years 1 month 24 days
Number of options exercisable (in shares)	984,380
Options exercisable, weighted average remaining contractual term	4 years 10 months 13 days
Exercise price 0.23 - 10.00 \| Minimum
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price (in usd per share)	$ 0.23
Exercise price 0.23 - 10.00 \| Maximum
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price (in usd per share)	$ 10
Exercise price 10.01 - 20.00
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of options outstanding (in shares)	3,205,758
Options outstanding, weighted average remaining contractual term	6 years 9 months 29 days
Number of options exercisable (in shares)	869,058
Options exercisable, weighted average remaining contractual term	5 years 10 months 2 days
Exercise price 10.01 - 20.00 \| Minimum
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price (in usd per share)	$ 10.01
Exercise price 10.01 - 20.00 \| Maximum
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price (in usd per share)	$ 20
Exercise price 20.01 - 30.00
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of options outstanding (in shares)	2,933,518
Options outstanding, weighted average remaining contractual term	7 years 4 months 24 days
Number of options exercisable (in shares)	1,225,951
Options exercisable, weighted average remaining contractual term	6 years 6 months 25 days
Exercise price 20.01 - 30.00 \| Minimum
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price (in usd per share)	$ 20.01
Exercise price 20.01 - 30.00 \| Maximum
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price (in usd per share)	$ 30
Exercise price 30.01 - 40.00
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of options outstanding (in shares)	424,414
Options outstanding, weighted average remaining contractual term	8 years 6 months 21 days
Number of options exercisable (in shares)	138,534
Options exercisable, weighted average remaining contractual term	8 years 5 months 19 days
Exercise price 30.01 - 40.00 \| Minimum
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price (in usd per share)	$ 30.01
Exercise price 30.01 - 40.00 \| Maximum
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price (in usd per share)	$ 40
Exercise price 40.01 - 50.00
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of options outstanding (in shares)	1,347,064
Options outstanding, weighted average remaining contractual term	9 years 3 months 14 days
Number of options exercisable (in shares)	0
Exercise price 40.01 - 50.00 \| Minimum
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price (in usd per share)	$ 40.01
Exercise price 40.01 - 50.00 \| Maximum
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price (in usd per share)	$ 50
Exercise price 50.01 - 60.00
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of options outstanding (in shares)	44,380
Options outstanding, weighted average remaining contractual term	9 years 4 months 20 days
Number of options exercisable (in shares)	0
Exercise price 50.01 - 60.00 \| Minimum
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price (in usd per share)	$ 50.01
Exercise price 50.01 - 60.00 \| Maximum
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price (in usd per share)	$ 60
Exercise price 60.01 - 90.00
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of options outstanding (in shares)	138,760
Options outstanding, weighted average remaining contractual term	9 years 8 months 12 days
Number of options exercisable (in shares)	0
Exercise price 60.01 - 90.00 \| Minimum
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price (in usd per share)	$ 60.01
Exercise price 60.01 - 90.00 \| Maximum
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price (in usd per share)	$ 90

Financial Expenses, Net (Detail

Financial Expenses, Net (Details) - USD ($) $ in Thousands	12 Months Ended
Financial Expenses, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Financial expenses:
Interest expense	$ (13,718)	$ (13,491)	$ (10,261)
Amortization of credit facility costs	(156)	(2,777)	(1,111)
Foreign currency transaction losses	(431)	(398)	0
Others	(338)	(242)	(321)
Financial expenses	(14,643)	(16,908)	(11,693)
Financial income:
Amortization of treasury bills premium	2,331	1,986	859
Foreign currency remeasurement loss (gain)	0	0	549
Interest income	4,402	2,652	1,116
Financial income	6,733	4,638	2,524
Total financial expenses, net	$ (7,910)	$ (12,270)	$ (9,169)

Basic and Diluted Net Loss Pe_3

Basic and Diluted Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Ordinary Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended												12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Earnings Per Share [Abstract]
Net income (loss) attributable to ordinary shares as reported	$ 4,260	$ 1,930	$ (1,270)	$ (12,150)	$ (15,631)	$ (11,694)	$ (15,510)	$ (20,724)	$ (10,945)	$ (11,498)	$ (21,174)	$ (18,045)	$ (7,230)	$ (63,559)	$ (61,662)
Shares used in computing net income (loss) per ordinary share, basic and diluted (in shares)					93,083,298	92,911,375	91,331,862	89,985,612	89,389,364	89,125,646	88,218,868	87,452,983	97,237,549	91,828,043	88,546,719
Net income (loss) per ordinary share, basic and diluted (in usd per share)					$ (0.17)	$ (0.13)	$ (0.17)	$ (0.23)	$ (0.12)	$ (0.13)	$ (0.24)	$ (0.21)	$ (0.07)	$ (0.69)	$ (0.70)

Basic and Diluted Net Loss Pe_4

Basic and Diluted Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential anti-dilutive shares (in shares)	9,193,339	8,983,178	5,221,894
Option
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential anti-dilutive shares (in shares)	8,041,159	7,744,521	4,195,762
RSUs
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential anti-dilutive shares (in shares)	1,152,180	1,238,657	641,358
Warrant
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential anti-dilutive shares (in shares)	0	0	384,774

Supplemental Information - Sche

Supplemental Information - Schedule of Long-Lived Assets by Location (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	$ 17,026	$ 15,366	$ 18,067
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	8,896	8,289	10,372
Switzerland
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	3,067	2,513	5,114
Israel
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	2,753	2,236	2,081
Germany
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	729	1,054	190
Others
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	$ 1,581	$ 1,274	$ 310

Supplemental Information - Sc_2

Supplemental Information - Schedule of Revenues by Geographic Region (Details) - USD ($) $ in Thousands	3 Months Ended												12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	$ 99,234	$ 92,062	$ 86,713	$ 73,309	$ 69,674	$ 64,756	$ 61,514	$ 52,125	$ 53,661	$ 50,109	$ 38,376	$ 34,880	$ 351,318	$ 248,069	$ 177,026
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues													232,805	168,414	134,688
Germany
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues													86,564	67,849	40,215
EMEA
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues													8,782	4,653	1,820
Japan
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues													17,912	6,351	303
Greater China
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues													$ 5,255	$ 802	$ 0

Selected Quarterly Financial _3

Selected Quarterly Financial Information (Unaudited) - Summary of Selected Quarterly Financial Information (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended												12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Selected Quarterly Financial Information [Abstract]
Net revenues	$ 99,234	$ 92,062	$ 86,713	$ 73,309	$ 69,674	$ 64,756	$ 61,514	$ 52,125	$ 53,661	$ 50,109	$ 38,376	$ 34,880	$ 351,318	$ 248,069	$ 177,026
Gross profit	74,448	69,162	65,607	53,495	46,646	45,807	41,681	33,887	38,021	34,956	25,224	23,216	262,712	168,021	121,417
Operating income (loss)	153	3,855	1,196	(6,118)	(8,664)	(5,246)	(7,085)	(12,677)	(4,506)	(5,919)	(15,530)	(13,373)	(914)	(33,672)	(39,328)
Net income (loss)	$ 4,260	$ 1,930	$ (1,270)	$ (12,150)	$ (15,631)	$ (11,694)	$ (15,510)	$ (20,724)	$ (10,945)	$ (11,498)	$ (21,174)	$ (18,045)	$ (7,230)	$ (63,559)	$ (61,662)
Basic net income (loss) per ordinary share (in usd per share)	$ 0.04	$ 0.02	$ (0.01)	$ (0.13)
Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares)	99,226,445	98,485,519	96,356,317	94,811,282
Diluted net income (loss) per ordinary share (in usd per share)	$ 0.04	$ 0.02	$ (0.01)	$ (0.13)
Weighted average number of ordinary shares used in computing diluted net income (loss) per share (in shares)	107,911,519	107,604,578	96,356,317	94,811,282

Uncategorized Items - nvcr-2019

Label	Element	Value
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ 2,162,000
Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ 2,162,000